<SEC-DOCUMENT>0001104659-20-132516.txt : 20201204
<SEC-HEADER>0001104659-20-132516.hdr.sgml : 20201204
<ACCEPTANCE-DATETIME>20201204172524
ACCESSION NUMBER:		0001104659-20-132516
CONFORMED SUBMISSION TYPE:	SUPPL
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20201204
DATE AS OF CHANGE:		20201204
EFFECTIVENESS DATE:		20201204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SUPPL
		SEC ACT:		
		SEC FILE NUMBER:	333-239025
		FILM NUMBER:		201370733

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>SUPPL
<SEQUENCE>1
<FILENAME>tm2037777-1_suppl.htm
<DESCRIPTION>SUPPL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Filed
pursuant to General Instruction II.L of Form F-10</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>File
No. 333-239025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(To
Base Shelf Prospectus dated June 12, 2020)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 105px; width: 240px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
<FONT STYLE="font-size: 10pt"><B>US$30,300,000</B></FONT></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
<FONT STYLE="font-size: 10pt"><B>Common Shares</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Oncolytics
Biotech Inc. (&ldquo;<B>Oncolytics</B>&rdquo; or the &ldquo;<B>Corporation</B>&rdquo;) has entered into an equity distribution
agreement dated June 15, 2020 (the &ldquo;<B>Equity Distribution Agreement</B>&rdquo;) with Canaccord Genuity LLC (the &ldquo;<B>Agent</B>&rdquo;)
relating to our common shares (&ldquo;<B>Common Shares</B>&rdquo;) pursuant to which we may offer and sell Common Shares having
an aggregate offering price of up to US$40,000,000. This Prospectus Supplement qualifies for distribution an aggregate of up to
US$30,300,000 of our Common Shares that may be offered and sold through the Agent, as our agent, under the Equity Distribution
Agreement (the &ldquo;<B>Offering</B>&rdquo;). See &ldquo;<I>Plan of Distribution</I>&rdquo; beginning on page S-19 of this Prospectus
Supplement for more information regarding these arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Common Shares are listed on the Nasdaq Capital Market (&ldquo;<B>NASDAQ</B>&rdquo;) under the symbol &ldquo;ONCY&rdquo; and on
the Toronto Stock Exchange (&ldquo;<B>TSX</B>&rdquo;) under the symbol &ldquo;ONC&rdquo;. On December 3, 2020, the last reported
sale price of our Common Shares was US$3.63 per Common Share on NASDAQ and C$4.60 per Common Share on the TSX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
delivery of a placement notice by us, if any, the Agent may sell the Common Shares in the United States only and such sales will
only be made by transactions that may be considered to be &ldquo;at-the-market distributions&rdquo; as defined in National Instrument
44-102 &ndash; <I>Shelf Distributions</I> (&ldquo;<B>NI 44-102</B>&rdquo;), including, without limitation, sales made directly
on NASDAQ, or on any other existing trading market for the Common Shares in the United States. No Common Shares will be sold on
the TSX or on other trading markets in Canada as at-the-market distributions. The Agent will make all sales using commercially
reasonable efforts consistent with their normal sales and trading practices and on mutually agreed upon terms between the Agent
and us. The Common Shares will be distributed at the market prices prevailing at the time of the sale of such Common Shares. As
a result, prices may vary as between purchasers and during the period of distribution. There is no arrangement for funds to be
received in escrow, trust or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
compensation to the Agent for sales of our Common Shares under this Prospectus Supplement will not exceed three percent (3%) of
the gross proceeds from the sale of such Common Shares. See &ldquo;<I>Plan of Distribution</I>&rdquo; in this Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
net proceeds, if any, from sales under this Prospectus Supplement will be used as described under the section titled &ldquo;<I>Use
of Proceeds</I>&rdquo; in this Prospectus Supplement. The proceeds we receive from sales will depend on the number of Common Shares
actually sold and the offering price of such Common Shares. We estimate the total expenses of this Offering, excluding the Agent&rsquo;s
fee, will be approximately US$200,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with the sale of the Common Shares on our behalf, the Agent will be deemed to be an &ldquo;underwriter&rdquo; within
the meaning of Section 2(a)(11) of the <I>U.S. Securities Act of 1933, as amended</I> (the &ldquo;<B>U.S. Securities Act</B>&rdquo;),
and the compensation of the Agent will be deemed to be an underwriting commission or discount. We have agreed to provide indemnification
and contribution to the Agent against certain liabilities, including liabilities under the U.S. Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Neither
the Agent, nor any of its affiliates or any person or company acting jointly or in concert with the Agent, has over-alloted, or
will over-allot, Common Shares in connection with the Offering or effect any other transactions that are intended to stabilize
or maintain the market price of the Common Shares.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>An
investment in the Common Shares is speculative and bears certain risks. See &ldquo;<I>Risk Factors</I>&rdquo; on beginning on
page S-10 in this Prospectus Supplement and on page 6 of the accompanying Prospectus. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>This
Offering is made by a Canadian issuer that is permitted, under a multijurisdictional disclosure system adopted by the United States
and Canada (&ldquo;MJDS&rdquo;), to prepare this Prospectus Supplement and the Prospectus in accordance with Canadian disclosure
requirements. Prospective investors in the United States should be aware that such requirements are different from those of the
United States. Financial statements included or incorporated by reference in the Prospectus have been prepared in accordance with
International Financial Reporting Standards as issued by the International Accounting Standards Board and may not be comparable
to financial statements of United States companies. Such financial statements are subject to auditor independence standards, in
addition to the standards of the Public Company Accounting Oversight Board (United States) and the United States Securities and
Exchange Commission (&ldquo;SEC&rdquo;) independence standards.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Prospective
investors should be aware that the acquisition of the Common Shares described herein may have tax consequences both in the United
States and in Canada. Such consequences for investors who are resident in, or citizens of, the United States may not be described
fully herein. This Prospectus Supplement and the Prospectus may not describe these tax consequences fully. You should read the
tax discussion under the headings &ldquo;<I>Certain Canadian Federal Income Tax Considerations</I>&rdquo; and &ldquo;<I>Material
United States Federal Income Tax Considerations</I>&rdquo; in this Prospectus Supplement.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
enforcement by investors of civil liabilities under the United States federal securities laws may be affected adversely by the
fact that the Corporation is incorporated under the laws of Alberta, Canada, that the majority of its officers and directors are
residents of Canada, that many of the experts named in this Prospectus Supplement and the Prospectus are not residents of the
United States, and that a substantial portion of the assets of the Corporation and said persons are located outside the United
States. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NEITHER
THE SEC NOR ANY STATE OR CANADIAN SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THE SECURITIES OFFERED HEREBY OR DETERMINED
IF THIS PROSPECTUS SUPPLEMENT OR THE ACCOMPANYING PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENCE. </B>Messrs. Wayne Pisano and Leonard Kruimer and Drs. William G. Rice and Bernd R. Seizinger are directors of
the Corporation who reside outside of Canada. Messrs. Pisano and Kruimer and Drs. Rice and Seizinger have appointed the Corporation,
at its principal place of business, as agent for service of process. Purchasers are advised that it may not be possible for investors
to enforce judgments obtained in Canada against any person that resides outside of Canada, even if the party has appointed an
agent for service of process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
financial information of the Corporation incorporated by reference in the Prospectus is presented in Canadian dollars. Unless
otherwise noted herein, all references to &ldquo;US$&rdquo;, &ldquo;United States dollars&rdquo; or &ldquo;US dollars&rdquo; are
to United States dollars and all references to &ldquo;C$&rdquo; are to Canadian dollars. See &ldquo;<I>Currency and Exchange Rate
Information</I>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
head office and principal place of business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N 1X7. Our registered
office is located at 4000, 421 - 7<SUP>th</SUP> Avenue S.W., Calgary, Alberta, T2P 4K9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Canaccord
Genuity</B></FONT></P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
date of this Prospectus Supplement is December 4, 2020.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><U>Prospectus
Supplement</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_001"><FONT STYLE="font-family: Times New Roman, Times, Serif">IMPORTANT
    NOTICE ABOUT INFORMATION IN THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_001"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-4</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_002"><FONT STYLE="font-family: Times New Roman, Times, Serif">FORWARD-LOOKING
    STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_002"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-4</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_003"><FONT STYLE="font-family: Times New Roman, Times, Serif">DOCUMENTS
    INCORPORATED BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_003"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-6</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_003"><FONT STYLE="font-family: Times New Roman, Times, Serif">DOCUMENTS
    FILED AS PART OF THE REGISTRATION STATEMENT</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_003"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-7</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_005"><FONT STYLE="font-family: Times New Roman, Times, Serif">CURRENCY
    AND EXCHANGE RATE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_005"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-7</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_006"><FONT STYLE="font-family: Times New Roman, Times, Serif">OFFERING
    SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_006"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-9</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_007"><FONT STYLE="font-family: Times New Roman, Times, Serif">RISK
    FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_007"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-10</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_008"><FONT STYLE="font-family: Times New Roman, Times, Serif">THE
    CORPORATION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_008"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-11</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_009"><FONT STYLE="font-family: Times New Roman, Times, Serif">BUSINESS
    OF THE CORPORATION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_009"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-13</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_010"><FONT STYLE="font-family: Times New Roman, Times, Serif">USE
    OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_010"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-17</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_011"><FONT STYLE="font-family: Times New Roman, Times, Serif">CONSOLIDATED
    CAPITALIZATION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_011"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-18</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_012"><FONT STYLE="font-family: Times New Roman, Times, Serif">TRADING
    PRICE AND VOLUME</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_012"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-18</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_013"><FONT STYLE="font-family: Times New Roman, Times, Serif">PRIOR
    SALES</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_013"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-18</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_014"><FONT STYLE="font-family: Times New Roman, Times, Serif">PLAN
    OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_014"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-19</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_015"><FONT STYLE="font-family: Times New Roman, Times, Serif">CERTAIN
    CANADIAN FEDERAL INCOME TAX CONSIDERATIONS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_015"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-20</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_016"><FONT STYLE="font-family: Times New Roman, Times, Serif">MATERIAL
    UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_016"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-22</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_017"><FONT STYLE="font-family: Times New Roman, Times, Serif">STATUTORY
    RIGHTS OF WITHDRAWAL AND RESCISSION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_017"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-29</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_018"><FONT STYLE="font-family: Times New Roman, Times, Serif">WHERE
    YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_018"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-29</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_019"><FONT STYLE="font-family: Times New Roman, Times, Serif">LEGAL
    MATTERS AND INTEREST OF EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_019"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-30</FONT></A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#s_020"><FONT STYLE="font-family: Times New Roman, Times, Serif">AGENT
    FOR SERVICE OF PROCESS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#s_020"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-30</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><U>Base
Shelf Prospectus dated June 12, 2020</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0; width: 90%"><FONT STYLE="font-size: 10pt"><A HREF="#a_001">ABOUT
    THIS PROSPECTUS AND OTHER MATTERS</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase; width: 10%"><FONT STYLE="font-size: 10pt"><A HREF="#a_001">4</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_002">FORWARD-LOOKING
    STATEMENTS</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_002">4</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_003">RISK FACTORS</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_003">6</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_004">DOCUMENTS
    INCORPORATED BY REFERENCE</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_004">6</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_005">DOCUMENTS
    FILED AS PART OF THE REGISTRATION STATEMENT</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_005">8</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_006">ADDITIONAL
    INFORMATION</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_006">8</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_007">THE CORPORATION</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_007">8</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_008">BUSINESS
    OF THE CORPORATION</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_008">9</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_009">CONSOLIDATED
    CAPITALIZATION</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_009">11</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_010">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_010">11</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_011">DESCRIPTION
    OF SHARE CAPITAL</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_011">11</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_012">DESCRIPTION
    OF SUBSCRIPTION RECEIPTS</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_012">12</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_013">DESCRIPTION
    OF WARRANTS</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_013">13</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_014">DESCRIPTION
    OF UNITS</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_014">13</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_015">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_015">14</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_016">PRIOR SALES</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_016">15</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_017">TRADING PRICE
    AND VOLUME</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_017">15</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_018">CERTAIN INCOME
    TAX CONSIDERATIONS</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_018">15</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_019">LEGAL MATTERS
    AND INTEREST OF EXPERTS</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_019">15</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_020">AUDITORS,
    TRANSFER AGENT AND REGISTRAR</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_020">16</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_021">ENFORCEABILITY
    OF CIVIL LIABILITIES AGAINST NON-U.S. PERSONS</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_021">16</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><FONT STYLE="font-size: 10pt"><A HREF="#a_022">AGENT FOR
    SERVICE OF PROCESS</A></FONT></TD>
    <TD STYLE="padding: 0; text-align: right; text-transform: uppercase"><FONT STYLE="font-size: 10pt"><A HREF="#a_022">16</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_001"></A>IMPORTANT
NOTICE ABOUT INFORMATION IN THIS PROSPECTUS SUPPLEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
document is in two parts. The first part is this Prospectus Supplement, which describes the specific terms of the Offering and
Common Shares and the method of distribution of the Common Shares and also supplements and updates information regarding Oncolytics
Biotech Inc. contained and incorporated by reference in the Prospectus. The second part is the accompanying Prospectus, which
gives more general information, some of which may not apply to the Common Shares. Both documents contain important information
you should consider when making your investment decision. If the description of the Common Shares varies between this Prospectus
Supplement and the accompanying Prospectus, investors should rely on the information in this Prospectus Supplement. This Prospectus
Supplement is deemed to be incorporated by reference into the Prospectus solely for the purpose of the Offering. If information
in this Prospectus Supplement is inconsistent with the Prospectus or the information incorporated by reference in the Prospectus,
you should rely on this Prospectus Supplement. You should read both this Prospectus Supplement and the accompanying Prospectus,
together with the additional information about us to which we refer you in the section of this Prospectus Supplement entitled
 &ldquo;<I>Where You Can Find Additional Information</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>You
should rely only on the information contained in this Prospectus Supplement, the Prospectus and the documents incorporated by
reference in the Prospectus. Neither the Corporation nor the Agent have authorized anyone to provide you with different information.
If anyone provides you with any different or inconsistent information, you should not rely on it. The Corporation is offering
the Common Shares only in jurisdictions where such offers are permitted by law.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>You
should assume that the information contained in this Prospectus Supplement, the Prospectus and the documents incorporated by reference
in the Prospectus is accurate only as of their respective dates, regardless of the time of delivery of this Prospectus Supplement
and the accompanying Prospectus. </B>Our business, financial condition, results of operations and prospects may have changed since
those dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Market
data and certain industry forecasts used in this Prospectus Supplement, the Prospectus and the documents incorporated by reference
in the Prospectus were obtained from market research, publicly available information and industry publications. We believe that
these sources are generally reliable, but the accuracy and completeness of this information is not guaranteed. We have not independently
verified such information, and we do not make any representation as to the accuracy of such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
this Prospectus Supplement, &ldquo;<B>Oncolytics</B>,&rdquo; the &ldquo;<B>Corporation</B>,&rdquo; &ldquo;<B>we</B>,&rdquo; &ldquo;<B>us</B>,&rdquo;
and &ldquo;our&rdquo; refer to Oncolytics Biotech Inc. and its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_002"></A>FORWARD-LOOKING
STATEMENTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Prospectus Supplement, the Prospectus and the documents incorporated by reference in the Prospectus contain certain statements
relating to future events or the Corporation&rsquo;s future performance which constitute forward-looking statements. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or
achievements of the Corporation, or industry results, to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts,
and include, but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations
with respect to the efficacy of our technologies; the timing and results of clinical studies related to our technologies; future
operations, products and services; the impact of regulatory initiatives on our operations; the size of and opportunities related
to the markets for our technologies; general industry and macroeconomic growth rates; expectations related to possible joint and/or
strategic ventures and statements regarding future performance. Forward-looking statements generally, but not always, are identified
by the words &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo;
 &ldquo;projects&rdquo;, &ldquo;potential&rdquo;, &ldquo;possible&rdquo; and similar expressions, or that events or conditions
 &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;could&rdquo; or &ldquo;should&rdquo; occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
forward-looking statements in this Prospectus Supplement, the Prospectus and the documents incorporated by reference in the Prospectus
are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond the Corporation&rsquo;s
control, including without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to all of our products, including pelareorep, being in the research and development
stage and requiring further development and testing before they can be marketed commercially;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks inherent in pharmaceutical research and development;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to timing and possible delays in our clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to some of our clinical trials being conducted in, and subject to the laws of, foreign
countries;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our pharmaceutical products being subject to intense regulatory approval processes
in the United States and other foreign jurisdictions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to being subject to government manufacturing and testing regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the extremely competitive biotechnology industry and our competition with larger
companies with greater resources;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our reliance on patents and proprietary rights to protect our technology;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to potential product liability claims;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our limited manufacturing experience and reliance on third parties to commercially
manufacture our products, if and when developed;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our new products not being accepted by the medical community or consumers;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our technologies becoming obsolete;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our dependence on third party relationships for research and clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our license, development, supply and distribution agreement with Adlai Nortye
Biopharma Co. Ltd.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our lack of operating revenues and history of losses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">uncertainty regarding our ability to obtain third-party reimbursement for the costs of our product;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to other third-party arrangements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our ability to obtain additional financing to fund future research and development
of our products and to meet ongoing capital requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to potential increases in the cost of director and officer liability insurance;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our dependence on key employees and collaborators;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to Barbados law, including those relating to the enforcement of judgments obtained
in Canada or the United States;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the effect of changes in the law on our corporate structure;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to expenses in foreign currencies and our exposure to foreign currency exchange rate
fluctuations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to data privacy laws;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our information technology systems and security breaches;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our compliance with the Sarbanes-Oxley Act of 2002, as amended;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our status as a foreign private issuer;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to possible &ldquo;passive foreign investment company&rdquo; status;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to fluctuations in interest rates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to information technology systems;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to business interruptions resulting from pandemics and public health emergencies,
including those related to COVID-19 coronavirus, geopolitical actions, including war and terrorism or natural disasters including
earthquakes, typhoons, floods and fires; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our Common Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
list is not exhaustive of the factors that may affect any of the Corporation&rsquo;s forward-looking statements. Some of the important
risks and uncertainties that could affect forward-looking statements are described further under the heading &ldquo;<I>Risk Factors</I>&rdquo;
in this Prospectus Supplement, in the Prospectus and in the Corporation&rsquo;s Annual Report (as defined below). If one or more
of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, our actual results may vary materially
from those expected, estimated or projected. Forward-looking statements in this document are not a prediction of future events
or circumstances, and those future events or circumstances may not occur. Given these uncertainties, users of the information
included herein, including investors and prospective investors, are cautioned not to place undue reliance on such forward-looking
statements. Investors should consult our quarterly and annual filings with the securities commissions or similar regulatory authorities
in Canada and the SEC for additional information on risks and uncertainties relating to forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Corporation cautions that the foregoing list of factors that may affect future results is not exhaustive. The forward-looking
information contained in this Prospectus Supplement, the Prospectus and the documents incorporated by reference in the Prospectus
is made as of the date of such documents. The forward-looking information contained in this Prospectus Supplement, the Prospectus
and in the documents incorporated by reference in the Prospectus is expressly qualified by this cautionary statement. The Corporation
does not undertake any obligation to publicly update or revise any forward-looking information except as required pursuant to
applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_003"></A>DOCUMENTS
INCORPORATED BY REFERENCE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>This
Prospectus Supplement is deemed to be incorporated by reference into the Prospectus solely for the purposes of the Offering.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Information
has been incorporated by reference in the Prospectus from documents filed with securities commissions or similar authorities in
Canada. </B>Copies of the documents incorporated herein by reference may be obtained on request without charge from our Corporate
Secretary at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N 1X7 telephone (403) 670-7377, and are available electronically
under the Corporation&rsquo;s profile on SEDAR (<U>www.sedar.com</U>) and on EDGAR (<U>www.sec.gov/edgar.shtml</U>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following documents, filed with the securities commissions or similar regulatory authorities in each of the provinces of Canada
and filed with, or furnished to, the SEC are specifically incorporated by reference into, and form an integral part of, the Prospectus:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our <A HREF="http://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/oncyf2019-20f.htm" STYLE="-sec-extract: exhibit">annual report</A> on Form 20-F (&quot;<B>Annual Report</B>&quot;) dated March 6, 2020, for the
year ended December 31, 2019 (filed in Canada with certain Canadian securities regulatory authorities as our annual information
form for the year ended December 31, 2019);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our <A HREF="http://www.sec.gov/Archives/edgar/data/1129928/000110465920048027/tm2016145-1_ex991.htm" STYLE="-sec-extract: exhibit">management information circular</A> dated March 16, 2020 relating to the annual general meeting
of shareholders held on May 7, 2020;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our <A HREF="http://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/oncyf2019-20f.htm" STYLE="-sec-extract: exhibit">audited consolidated financial statements</A>, together with the notes thereto, as at December
31, 2019 and 2018, which comprise the consolidated statements of financial position as at December 31, 2019 and 2018, and the consolidated
statements of loss and comprehensive loss, changes in equity, and cash flows for the years ended December 31, 2019, 2018 and 2017,
together with the independent auditors' report thereon; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our <A HREF="http://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex151-2019mda.htm" STYLE="-sec-extract: exhibit">management's discussion and analysis</A> of financial condition and results of operations dated
March 5, 2020, for the year ended December 31, 2019;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our <A HREF="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000062/ex991-interimfsseptemb.htm" STYLE="-sec-extract: exhibit">unaudited interim consolidated financial statements</A>, together with the notes thereto, as at
September 30, 2020, which comprise the interim consolidated statements of financial position as at September 30, 2020 and December
31, 2019, and the interim consolidated statements of loss and comprehensive loss, changes in equity, and cash flows for the three
and nine months ended September 30, 2020 and 2019; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our <A HREF="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000062/ex992-q32020mda.htm" STYLE="-sec-extract: exhibit">management's discussion and analysis</A> of financial condition and results of operations dated
November 3, 2020, for the nine months ended September 30, 2020.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
documents of the type required by National Instrument 44-101 - <I>Short Form Prospectus Distributions</I> to be incorporated by
reference in a short form Prospectus, including any annual information form, annual report on Form 20-F, comparative annual consolidated
financial statements and the auditors&rsquo; report thereon, comparative interim consolidated financial statements, management&rsquo;s
discussion and analysis of financial condition and results of operations, material change report (except a confidential material
change report), business acquisition report and information circular, if filed by us with the securities commissions or similar
authorities in Canada after the date of this Prospectus Supplement and prior to the date on which the Offering under this Prospectus
Supplement ends, shall be deemed to be incorporated by reference in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, to the extent that any document or information incorporated by reference in the Prospectus is included in any report
filed with or furnished to the SEC pursuant to the United States Securities Exchange Act of 1934, as amended (the &ldquo;<B>U.S.
Exchange Act</B>&rdquo;), after the date of this Prospectus Supplement and prior to the date on which the Offering under this
Prospectus Supplement ends, such document or information shall be deemed to be incorporated by reference as an exhibit to the
registration statement of which this Prospectus Supplement and the Prospectus forms a part (in the case of documents or information
deemed furnished on Form 6-K or Form 8-K, only to the extent specifically stated therein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Any
statement contained in this Prospectus Supplement, the Prospectus or in a document incorporated or deemed to be incorporated by
reference in the Prospectus shall be deemed to be modified or superseded for the purposes of this Prospectus Supplement and the
Prospectus to the extent that a statement contained herein or in any other subsequently filed document which also is, or is deemed
to be, incorporated by reference in the Prospectus or therein modifies or supersedes such statement. The modifying or superseding
statement need not state that it has modified or superseded a prior statement or include any other information set forth in the
document that it modifies or supersedes. The making of a modifying or superseding statement shall not be deemed an admission for
any purposes that the modified or superseded statement, when made, constituted a misrepresentation, an untrue statement of a material
fact or an omission to state a material fact that was required to be stated or that was necessary to make a statement not misleading
in light of the circumstances in which it was made. Any statement so modified or superseded shall not be deemed, except as so
modified or superseded, to constitute a part of this Prospectus Supplement or the Prospectus.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_004"></A>DOCUMENTS
FILED AS PART OF THE REGISTRATION STATEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following documents have been or will be filed with the SEC as part of the registration statement of which this Prospectus Supplement
and the Prospectus forms a part: (i) the documents set out under the heading &ldquo;<I>Documents Incorporated by Reference</I>&rdquo;
in this Prospectus Supplement and the Prospectus; (ii) the consents of the Corporation&rsquo;s auditor; (iii) the powers of attorney
from the directors and certain officers of the Corporation and (iv) the Equity Distribution Agreement described in this Prospectus
Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_005"></A>CURRENCY
AND EXCHANGE RATE INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
this Prospectus Supplement and the accompanying Prospectus, unless otherwise indicated, all dollar amounts and references to &ldquo;US$&rdquo;
are to U.S. dollars and references to &ldquo;C$&rdquo; are to Canadian dollars. This Prospectus Supplement and the accompanying
Prospectus and the documents incorporated by reference in the Prospectus contain translations of some Canadian dollar amounts
into U.S. dollars solely for your convenience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth, for the periods indicated, the high, low, average and period-end rates of exchange for US$1.00, expressed
in Canadian dollars, posted by the Bank of Canada:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD COLSPAN="9" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Year Ended December 31<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2017</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: left">Highest rate during the period</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1.3600</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1.3642</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1.3743</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Lowest rate during the period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1.2988</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1.2288</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1.2128</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Average rate for the period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1.3269</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1.2957</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1.2986</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Rate at the end of the period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1.2988</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1.3642</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1.2545</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Note:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Data
from the Bank of Canada reflects the daily average rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 3, 2020, the daily average exchange rate posted by the Bank of Canada for conversion of U.S. dollars into Canadian dollars
was US$1.00 = C$1.2880. Unless otherwise indicated, currency translation in this Prospectus Supplement reflect the December 3,
2020 rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>




<DIV STYLE="padding: 3px; border: Black 1pt solid">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_006"></A>OFFERING
SUMMARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 99%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Issuer:</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 72%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Oncolytics
    Biotech Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Offering:</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
    accordance with the Equity Distribution Agreement, we may offer and sell our Common Shares through the Agent, as agent, up
    to an aggregate offering amount of US$40,000,000. Common Shares having an aggregate Offering amount of up to US$30,300,000
    are being offered under this Prospectus Supplement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Manner
    of Offering:</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;At-the-market&rdquo;
    offering that may be made from time to time through our sales agent, the Agent. See &ldquo;<I>Plan of Distribution</I>&rdquo;
    on page S- 19.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common
    Shares Outstanding Before this Offering:</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">45,307,345
    Common Shares (non-diluted)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common
    Shares Outstanding Immediately Following this Offering:</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">53,654,452
    Common Shares (non-diluted) after the issuance of up to 8,347,107 Common Shares, assuming an aggregate of US$30,300,000 of
    our Common Shares are issued pursuant to the Offering at a sales price of US$3.63 per Common Share<B><SUP>(1)</SUP></B>. The
    actual number of Common Shares issued and outstanding will vary depending on the actual sales prices and aggregate dollar
    amount sold under the Offering.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Use
    of Proceeds:</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
    intend to use the net proceeds from the Offering, if any, for the advancement of the Corporation&rsquo;s clinical development
    program, related support costs and general corporate and administrative expenses. The amounts actually expended for the purposes
    described above may vary significantly depending upon a number of factors, including those listed under the heading &ldquo;Risk
    Factors&rdquo; in this Prospectus Supplement. See &ldquo;<I>Use of Proceeds</I>&rdquo;.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Listing
    Symbols:</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">NASDAQ:&#9;ONCY</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">TSX:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ONC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risk
    Factors:</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
    investment involves a high degree of risk. You should carefully read and consider the information set forth under the heading
    &ldquo;<I>Risk Factors</I>&rdquo; beginning on page S-10 of this Prospectus Supplement and on page 6 of the Prospectus.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Note:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 99%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unless
                                         otherwise stated, all information contained in this Prospectus Supplement reflects an
                                         assumed public offering price of US$3.63 per Common Share, which was the last reported
                                         sale price of our Common Shares on the NASDAQ on December 3, 2020.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_007"></A>RISK
FACTORS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prospective
purchasers of Common Shares should consider carefully the risk factors set out in this Prospectus Supplement, the Prospectus and
the documents incorporated by reference in the Prospectus. Discussions of certain risks affecting Oncolytics in connection with
its business are set forth under &ldquo;<I>Risk Factors</I>&rdquo; in the Prospectus and in our annual disclosure documents filed
with the various securities regulatory authorities which are incorporated by reference in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Volatility
of market price of the Common Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
market price of the Common Shares may be volatile. The volatility may affect the ability of holders of Common Shares to sell the
Common Shares at an advantageous price. Market price fluctuations in the Common Shares may be due to the Corporation&rsquo;s operating
results failing to meet the expectations of securities analysts or investors in any quarter, downward revision in securities analysts&rsquo;
estimates, governmental regulatory action, adverse change in general market conditions or economic trends, acquisitions, dispositions
or other material public announcements by the Corporation or its competitors, along with a variety of additional factors, including,
without limitation, those set forth under &ldquo;<I>Forward-Looking Statements</I>&rdquo; in this Prospectus Supplement. In addition,
the market price for securities in the stock markets, including the NASDAQ and the TSX, recently experienced significant price
and trading fluctuations. These fluctuations have resulted in volatility in the market prices of securities that often has been
unrelated or disproportionate to changes in operating performance. These broad market fluctuations may adversely affect the market
price of the Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
Corporation will have broad discretion over the use of the net proceeds from the Offering and the Corporation may not use these
proceeds in a manner desired by the Corporation&rsquo;s shareholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Management
will have broad discretion with respect to the use of the net proceeds from the Offering and investors will be relying on the
judgment of management regarding the application of these proceeds. Management could spend most of the net proceeds from the Offering
in ways that the Corporation&rsquo;s shareholders may not desire or that do not yield a favorable return. You will not have the
opportunity, as part of your investment in the Common Shares, to influence the manner in which the net proceeds of the Offering
are used. At the date of this Prospectus Supplement, the Corporation intend to use the net proceeds from the Offering as described
under the heading &ldquo;<I>Use of Proceeds</I>&rdquo;. However, the Corporation&rsquo;s needs may change as the business and
the industry the Corporation addresses evolve. As a result, the proceeds to be received in the Offering may be used in a manner
significantly different from the Corporation&rsquo;s current expectations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
Common Shares offered hereby will be sold in &ldquo;at-the-market&rdquo; offerings, and investors who buy Common Shares at different
times will likely pay different prices</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Investors
who purchase Common Shares in this Offering at different times will likely pay different prices, and so may experience different
outcomes in their investment results. The Corporation will have discretion, subject to market demand, to vary the timing, prices,
and numbers of Common Shares sold, and there is no minimum or maximum sales price. Investors may experience a decline in the value
of their Common Shares as a result of share sales made at prices lower than the prices they paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
Corporation does not currently intend to pay any cash dividends on the Common Shares; therefore, the Corporation&rsquo;s shareholders
may not be able to receive a return on their Common Shares until they sell them</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Corporation has not declared or paid any dividends since its incorporation. The Corporation currently intends to retain earnings,
if any, to finance the growth and development of its business and does not currently intend to pay cash dividends on the Common
Shares in the foreseeable future. Any return on an investment in the Common Shares will likely come from the appreciation, if
any, in the value of the Common Shares. The payment of future cash dividends, if any, will be reviewed periodically by our board
of directors and will depend upon, among other things, conditions then existing including earnings, financial condition and capital
requirements, restrictions in financing agreements, business opportunities and conditions and other factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>You
may be unable to enforce actions against us, certain of our directors and officers, or the experts named in this Prospectus Supplement
under U.S. federal securities laws.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are a company continued under the laws of the Province of Alberta, Canada. Most of our directors and officers as well as the certain
of the experts named in this Prospectus Supplement and the accompanying Prospectus, reside principally in Canada. Because all
or a substantial portion of our assets and the assets of these persons are located outside of the United States, it may not be
possible for you to effect service of process within the United States upon us or those persons. Furthermore, it may not be possible
for you to enforce against us or those persons in the United States, judgments obtained in U.S. courts based upon the civil liability
provisions of the U.S. federal securities laws or other laws of the United States. There is doubt as to the enforceability, in
original actions in Canadian courts, of liabilities based upon U.S. federal securities laws and as to the enforceability in Canadian
courts of judgments of U.S. courts obtained in actions based upon the civil liability provisions of the U.S. federal securities
laws. Therefore, it may not be possible to enforce those actions against us, certain of our directors and officers or certain
of the experts named in this Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
Corporation is likely a &ldquo;passive foreign investment company&rdquo; which may have adverse U.S. federal income tax consequences
for U.S. shareholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.
holders of Common Shares should be aware that the Corporation believes it was classified as a passive foreign investment company
(&ldquo;<B>PFIC</B>&rdquo;) during the tax year ended December 31, 2019, and based on current business plans and financial expectations,
the Corporation expects that it will be a PFIC for the current tax year and may be a PFIC in future tax years. If the Corporation
is a PFIC for any year during a U.S. shareholder&rsquo;s holding period of the Common Shares, then such U.S. shareholder generally
will be required to treat any gain realized upon a disposition of Common Shares, or any &ldquo;excess distribution&rdquo; received
on its Common Shares, as ordinary income, and to pay an interest charge on a portion of such gain or distribution, unless the
shareholder makes a timely and effective &ldquo;qualified electing fund&rdquo; election (&ldquo;<B>QEF Election</B>&rdquo;) or
a &ldquo;mark-to-market&rdquo; election with respect to the Common Shares. A U.S. shareholder who makes a QEF Election generally
must report on a current basis its share of the Corporation&rsquo;s net capital gain and ordinary earnings for any year in which
the Corporation is a PFIC, whether or not the Corporation distributes any amounts to its shareholders. A U.S. shareholder who
makes a mark-to-market election generally must include as ordinary income each year the excess of the fair market value of the
Common Shares over the taxpayer&rsquo;s adjusted tax basis therein. This paragraph is qualified in its entirety by the discussion
below under the heading &ldquo;<I>Material United States Federal Income Tax Considerations</I>.&rdquo; Each U.S. shareholder should
consult its own tax advisors regarding the PFIC rules and the U.S. federal income tax consequences of the acquisition, ownership,
and disposition of Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_008"></A>THE
CORPORATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Oncolytics
Biotech Inc. was incorporated pursuant to the ABCA on April&nbsp;2, 1998 as 779738 Alberta Ltd. On April&nbsp;8, 1998, we amended
our articles of incorporation (the &ldquo;<B>Articles</B>&rdquo;) and changed our name to Oncolytics Biotech Inc. On July&nbsp;29,
1999, we amended our Articles by removing the private company restrictions included therein and subdivided the 2,222,222 Common
Shares issued and outstanding into 6,750,000 Common Shares. On February&nbsp;9, 2007, we amended our Articles to permit shareholder
meetings to be held at any place in Alberta or at any other location as determined by our board of directors. On May 22, 2018,
we amended our Articles of Incorporation to effect a consolidation of the Common Shares on the basis of 9.5 pre-consolidation
Common Shares for each one post-consolidation Common Share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have two material operating subsidiaries: Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (US) Inc., a Delaware corporation.
Oncolytics Biotech (Barbados) Inc. is incorporated pursuant to the laws of Barbados and is a wholly-owned direct subsidiary of
the Corporation. Oncolytics Biotech (U.S.) Inc. is incorporated pursuant to the laws of Delaware and is a wholly-owned direct
subsidiary of Oncolytics Biotech (Barbados) Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
head office and principal place of business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7.
Our registered office is located at 4000, 421&nbsp;-&nbsp;7<SUP>th</SUP>&nbsp;Avenue S.W., Calgary, Alberta, T2P&nbsp;4K9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
October 27, 2020, we announced the launch of a multi-indication gastrointestinal phase 1/2 trial, known as GOBLET. It will be
managed by AIO-Studien-gGmbH, investigating pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab
(Tecentriq&reg;), in patients with metastatic pancreatic, metastatic colorectal, and advanced anal cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
primary endpoint of the study is safety, with overall response rate and blood-based biomarkers (T-cell clonality and CEACAM6)
as exploratory endpoints. Approximately 55 patients are planned for enrollment across four separate cohorts:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st line metastatic
Pancreatic cancer patients (n=12)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pelareorep in combination with atezolizumab in 2nd and 3rd line metastatic colorectal cancer patients
that are diagnosed as MSI high (microsatellite instability) (n=19)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pelareorep in combination with atezolizumab and TAS-102 in 3rd line metastatic colorectal cancer
patients (n=14)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients
(n=10).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
November 9, 2020, we announced the publication of an electronic poster at The Society for Immunotherapy of Cancer 35<SUP>th</SUP>
Anniversary Annual Meeting, which detailed clinical data from the AWARE-1 window-of-opportunity breast cancer study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Key
data and conclusions from the electronic poster include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Tumor-cell specific pelareorep replication was observed in all cohort-1 patients following systemic
pelareorep administration</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">70% of cohort 1 patients saw an increase in tumor cellularity and tumor-infiltrating lymphocytes,
the study's primary endpoint and a measure of tumor-associated cellularity and tumor-infiltrating lymphocytes that is associated
with favorable clinical outcomes</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On average, there was a 14-fold increase in intratumoral CD8+ T-cells from baseline (pre-pelareorep
administration) to surgery (21-days post-administration), with increases observed in all cohort-1 patients</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pelareorep administration led to the generation and expansion of new T-cell clones in the tumor
and periphery, which included both anti-tumor and anti-viral clones</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
November 19, 2020, we announced results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of
pelareorep and granulocyte-macrophage colony-stimulating factor (&ldquo;<B>GM-CSF</B>&rdquo;) alongside standard chemoradiotherapy
and adjuvant temozolomide for the treatment of glioblastoma multiforme (&ldquo;<B>GBM</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Key
data and conclusions from the presentation include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Evaluable patients treated at pelareorep dose level-2 (3x1010 TCID50) had an estimated median progression-free
survival (PFS) of 9.4 months (n=6; 95% CI: 4.2-10.6)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Evaluable patients treated at pelareorep dose level-1 (1x1010 TCID50) had an estimated median PFS
of 6.1 months (n=6; 95% CI: 4.9-9.2)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The estimated median PFS of all evaluable patients, regardless of pelareorep dose level, was 7.8
months (n=12; 95% CI: 4.9-9.7)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pelareorep, in addition to GM-CSF, standard chemoradiotherapy, and adjuvant temozolomide, was safe
and well-tolerated</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_009"></A>BUSINESS
OF THE CORPORATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company and we have focused our research
and development efforts related to pelareorep, a systemically administered immuno-oncology (&ldquo;<B>I-O</B>&rdquo;) viral agent
with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur
substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until, if
and when, pelareorep becomes commercially viable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
potential product for human use, pelareorep, an unmodified reovirus, is a first in class systemically administered I-O viral agent
for the treatment of solid tumors and hematological malignancies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Scientific
Background </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pelareorep&rsquo;s
anti-tumor activity is based on three modes of action which are complementary but not interdependent (see Figure 1, below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Selective viral replication in permissive cancer cells which leads to tumor cell lysis.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Activation of innate immunity in response to the infection which results in a cascade of chemokines/cytokines
causing natural killer (&ldquo;<B>NK</B>&rdquo;) cells to be activated and attack cancer cells.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A specific adaptive immune response triggered by tumor- and viral-associated antigens displayed
by antigen-presenting cells (&ldquo;<B>APCs</B>&rdquo;), infected tumor cells and/or dendritic cells to T-cells.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Summary
of Research and Development highlights </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preclinical
and translational research to date indicates the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pelareorep has anticancer effects in models of metastatic cancers that can prolong survival in
these models when using immuno-competent rodents.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The survival benefit in animal models can be enhanced when pelareorep is given in combination with
chemotherapy, immunotherapy or radiotherapy.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A toxic dose of pelareorep has not been reached/established in animal models and infection presents
with minimal side-effects.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical data to date indicate the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">More than 1,400 patients have been enrolled in clinical studies conducted in the US, Canada and
the European Union. Of these, more than 1,000 patients received pelareorep, with over 930 via intravenous (&ldquo;<B>IV</B>&rdquo;)
administration.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pelareorep has been administered as single or multiple doses (intratumoral or intravenous), either
as a mono-therapy or in combination with chemotherapy, immunotherapy (e.g., checkpoint inhibitors), and radiotherapy.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pelareorep is generally well-tolerated and has a manageable side effect profile for most patients.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">When combined with chemotherapeutic agents, pelareorep does not appear to enhance either the frequency
or severity of the adverse effects of the chemotherapeutic agents.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There is emerging evidence that pelareorep may impact overall survival (&ldquo;<B>OS</B>&rdquo;)
in metastatic breast cancer (&ldquo;<B>mBC</B>&rdquo;) and metastatic adenocarcinoma of the pancreas (&ldquo;<B>MAP</B>&rdquo;):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
                                         a randomized, controlled Phase 2 study of paclitaxel with pelareorep versus paclitaxel
                                         alone in mBC (Canadian Cancer Trials Group IND.213) the median OS was greater for subjects
                                         treated with paclitaxel and pelareorep (median 17.4 months) than subjects treated with
                                         paclitaxel alone (10.4 months, hazard ratio (&ldquo;<B>HR</B>&rdquo;) 0.65).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
                                         a single-arm study with gemcitabine plus pelareorep in first-line MAP (REO 017) the median
                                         OS was 10 months with a 1 year and 2-year survival of 46% and 24%, respectively.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
                                         a two-arm Phase 2 randomized study (NCI 8601), patients with MAP were randomized to receive
                                         either carboplatin, paclitaxel and pelareorep (test arm) or carboplatin and paclitaxel
                                         alone (control arm). The median OS was similar for both arms, but the probability of
                                         survival at Year 2 was 20% in the test arm vs 9% in the control arm.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Mechanism
of Action </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Figure
1. Proposed mechanism of action for pelareorep.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 358px; width: 447px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Direct
cell lysis - Reovirus Replication in Permissive Cancer Cells</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Selective
viral replication and lysis in cancer cells and not normal cells is mediated by the host cellular protein dsRNA-activated protein
kinase (&ldquo;<B>PKR</B>&rdquo;). In non-cancer cells that are infected with reovirus, PKR activates in the presence of the virus
which in turn inhibits viral gene translation. However, in permissive cancer cells, PKR activation is inhibited, allowing for
viral gene translation and eventual cell lysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">It
was originally established that selective lysis with reovirus was mediated by tumor cells with an activated rat sarcoma virus
oncogene (&ldquo;<B>RAS</B>&rdquo;) pathway, since active RAS inhibits PKR activation. However, more recent investigations have
revealed that reovirus replication is not just restricted to cells with an active RAS pathway, oncogenic mutations and amplifications
in upstream and downstream mediators of the RAS-pathway also allow for viral replication and oncolysis. Moreover, active RAS is
known to stimulate over 18 downstream effector proteins, many of which have been shown to facilitate viral replication. Cells
bearing dysfunctional or deleted tumor suppressor genes and or chemo- or radiation-induced cell stress also show increased sensitivity
to reovirus replication and lysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Induction
of Innate Immunity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preclinical
and clinical studies provide compelling evidence that pelareorep functions as an immunogenic agent. Indeed, preclinical studies
demonstrated that cancer cells infected with pelareorep can produce an innate immune response triggering the release of inflammatory
cytokines. This inflammatory environment promotes a chemotactic response in NK cells, dendritic cells, and cytotoxic T-cells,
altering the tumor microenvironment to support bystander immune-mediated cancer cell death. Intriguingly, preclinical studies
have also demonstrated that the beneficial immunogenic functions of pelareorep can occur independently of viral replication. Pelareorep
performs this immunogenic function, in part, by activating dendritic cells, key regulators of both adaptive and innate immunity.
Dendritic cells activated by reovirus, in turn, stimulate the innate antitumor activity of natural killer (&ldquo;<B>NK</B>&rdquo;)
cells and aid in the priming of specific antitumor cytotoxic lymphocyte, demonstrating that dendritic cell recognition of reovirus
may trigger a beneficial innate immune response.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
clinical trial with pelareorep (REO 013) provided an opportunity to study human NK cell activation in a controlled manner. Ten
colorectal cancer patients with liver metastases received between one and five doses of pelareorep prior to surgical resection
of their tumor. NK cell activation peaked 24-48 hours post-infection, coincident with a peak of pro-inflammatory cytokines. NK
cells within reovirus-treated blood mononuclear cells were stimulated to kill tumor targets, but not normal hepatocytes. Moreover,
peripheral blood mononuclear cells were able to hand-off virus to tumors for direct oncolytic killing. Similarly, NK cells within
liver mononuclear cells became selectively cytotoxic towards tumor cells when activated by reovirus. These results showed that
reovirus modulates human NK cell activity in vivo and suggest that this may contribute to the therapeutic effect of pelareorep.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Induction
of Adaptive Immunity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adaptive
anti-tumor immunity allows for elimination of existing cancer cells and performs constant surveillance, preventing relapse, and
increases OS. An adaptive immune response requires two signals: a signal from an APC, as well as a co-stimulation signal in the
form of cytokines. In the absence of both signals, the adaptive immune response fails. Therapy with pelareorep has the potential
to activate both signals. Following its therapeutic administration, pelareorep enhances the expression of &lsquo;foreign&rsquo;
antigens/markers on tumor cells. Oncolysis of tumor cells exposes tumor-associated antigens (&ldquo;<B>TAAs</B>&rdquo;) and viral-associated
antigens (&ldquo;<B>VAAs</B>&rdquo;) for processing and presentation by APCs, such as dendritic cells. Through the combined actions
of these immunological events, pelareorep facilitates the display of novel &lsquo;foreign&rsquo; antigens on the surface of infected
tumor cells and APCs. Simultaneously, pelareorep induces an inflammatory response promoting the expression of co-stimulatory molecules
and inflammatory cytokines. Together, pelareorep mediated immunological events over-rule tumor antigen presentation impairments
and initiate adaptive anti-tumor immunity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">By
promoting the expression of novel antigens and the release of inflammatory cytokines, pelareorep, promotes an inflamed tumor phenotype.
An inflamed tumor phenotype is characterized by NK and T-cell infiltration, increased expression of chemokines/ cytokines, and
increased expression of checkpoint ligands. This phenotype correlates with an increase in OS and has a positive prognostic value
for early stage cancers. In patients with metastatic cancer, an inflamed tumor phenotype is associated with better clinical outcomes
when treated with immunotherapies, including immune checkpoint blockade inhibitors, cancer vaccines, and adoptive T-cell therapies.
By promoting an inflamed tumor phenotype, pelareorep primes an anti-cancer immune response (see Figure 2, below).<I><BR STYLE="clear: both"></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Figure
2. Pelareorep primes an anti-cancer immune response</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 345px; width: 513px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Clinical
Development Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
ultimate objective of our clinical development plan is to obtain regulatory approval for pelareorep as quickly as possible and
is based on the compelling efficacy data from previous studies in breast, multiple myeloma, and selected gastrointestinal cancers.
Our clinical development program centers on key immunotherapy combinations. Specifically, immunotherapy combinations in which
pelareorep has the potential to provoke a specific innate and adaptive immune responses when combined with checkpoint blockade
therapy, chemotherapy and/or targeted therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
2017, we reported clinical results from our randomized clinical program which includes clinical study collaborations with the
Canadian Cancer Trials Group (formerly known as the National Cancer Institute of Canada). Specifically, subgroup analysis in the
IND 213 trial in mBC revealed a significant improvement in the OS of patients that are hormone receptor-positive (HR+) / human
epidermal growth factor receptor 2 negative (HER2-). In HR+/HER2- patients, pelareorep therapy, in combination with paclitaxel,
more than doubled the OS from 10.8 month with paclitaxel therapy alone, to 21.8 months with pelareorep plus paclitaxel. This increase
in OS is consistent with previous survival data reported from our U.S. NCI pancreatic trial which suggests a long-term survival
benefit when comparing test and control arms at 24 months, as well as test to historical data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
2019, we published our first data set from a clinical study that combined pelareorep with chemotherapy and pembrolizumab (Keytruda&reg;)
in patients with pancreatic cancer. This study, published in the journal of Clinical Cancer Research, demonstrated the safety
and tolerability of this combination treatment regime and showed encouraging clinical efficacy with one patient achieving a partial
response (six-month duration) and two patients with stable disease (lasting 126 and 221 days). In early 2019 we announced the
regulatory approval of the AWARE-1 study which examines the use of pelareorep and atezolizumab (Tecentriq&reg;) in a breast cancer
window-of -opportunity study. Preliminary results from AWARE-1 were presented at the Society for Immunotherapy of Cancer (SITC)
meeting in November 2019 and demonstrated pelareorep mediated priming of the tumor microenvironment for checkpoint blockade therapy.
In the second half of 2019, we initiated start-up activities for the BRACELET-1 (BReast cAnCEr with the Oncolytic Reovirus PeLareorEp
in CombinaTion with anti-PD-L1 and Paclitaxel) study which will essentially repeat IND 213 in HR+/HER2- patients, with the addition
of a third arm that includes pelareorep, paclitaxel and avelumab (Bavencio&reg;) in mBC. This study is expected to begin enrollment
in the first quarter of 2020. Additional studies in gastrointestinal indications are now being evaluated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Business
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
business strategy is to develop and market pelareorep in an effective and timely manner, and access additional technologies at
a time and in a manner that we believe is best for our development. We intend to achieve our business strategy by focusing on
these key areas:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Develop pelareorep through our clinical development plan assessing the safety and efficacy in human
subjects;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Establish collaborations with experts to assist us with scientific and clinical developments of
this new potential pharmaceutical product;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Implement strategic alliances with select biopharmaceutical companies and laboratories, at a time
and in a manner whereby such alliances may complement and expand our own research and development efforts. Such alliances may also
result in an eventual expansion to include providing additive sales and marketing capabilities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Utilize our broadening patent base and collaborator network as a mechanism to meet our strategic
objectives; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Develop relationships with companies that could be instrumental in assisting us to access other
innovative therapeutics.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
business strategy is based on attaining a number of commercial objectives, which, in turn, are supported by a number of product
development goals. In this Prospectus Supplement, statements of our &ldquo;belief&rdquo; are based primarily upon our results
derived to date from our research and development program with animals, early stage human trials and our most recent data in HR+/HER2-
mBC patients, upon which we believe that we have a reasonable scientific basis to expect the particular results to occur. It is
not possible to predict, based upon studies in animals, or early stage human trials, whether a new therapeutic will ultimately
prove to be safe and effective in humans. There are no assurances that the particular result expected by us will occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of the date hereof, we do not intend to become a fully integrated pharmaceutical company with substantial in-house research and
development, marketing and distribution or manufacturing capabilities. We are pursuing a strategy of establishing relationships
with larger companies as strategic partners. It is anticipated that future clinical development into large international or pivotal
trials would generally occur in conjunction with a strategic partner or partners, who would contribute expertise and financial
assistance. In exchange for certain product rights and commitments to market our products, the strategic partners would be expected
to share in proceeds from the sale of our product or products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_010"></A>USE
OF PROCEEDS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
net proceeds from the Offering are not determinable in light of the nature of the distribution. The net proceeds of any given
distribution of Common Shares through the Agent in an &ldquo;at-the-market distribution&rdquo; will represent the gross proceeds
after deducting the compensation payable to the Agent under the Equity Distribution Agreement and expenses of the distribution.
The Agent will receive a cash fee not exceeding three percent (3%) of the gross proceeds realized from the sale of our Common
Shares for services rendered in connection with the Offering. We estimate the total expenses of the Offering, excluding the fee
paid to the Agent, will be approximately US$250,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to use the net proceeds from the Offering, if any, for the advancement of the Corporation&rsquo;s clinical development
program, related support costs and general corporate and administrative expenses. General corporate and administrative expenses
may include funding ongoing operations and/or capital requirements, discretionary capital programs and potential future acquisitions.
Although, the Corporation intends to expend the net proceeds from the Offering as set forth above, there may be circumstances
where for sound business reasons, a reallocation of funds may be deemed prudent or necessary, and may vary materially from that
set forth above. Pending the uses described above, we plan to invest the net proceeds from the Offering in short- and intermediate-term,
interest bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the
U.S. government.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
amounts actually expended for the purposes described above may vary significantly depending upon a number of factors, including
those listed under the heading &ldquo;<I>Risk Factors</I>&rdquo; in this Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_011"></A>CONSOLIDATED
CAPITALIZATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
for the issuance of Common Shares of the Corporation as set forth under the heading &ldquo;<I>Prior Sales</I>&rdquo; in this Prospectus
Supplement, there has not been any material change in the share and loan capital of the Corporation, on a consolidated basis,
since the Corporation&rsquo;s most recently filed financial statements for the three and nine months ended September 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_012"></A>TRADING
PRICE AND VOLUME</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Common Shares are listed and posted for trading on the TSX under the trading symbol &ldquo;ONC&rdquo; and on the NASDAQ under
the trading symbol &ldquo;ONCY&rdquo;. On December 3, 2020, the closing bid price of our Common Shares on the NASDAQ was US$3.63
and the closing price of our Common Shares on the TSX was C$4.60.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth the market price ranges and the aggregate volume of trading of the Common Shares on the TSX and NASDAQ
for the periods indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">TSX</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">NASDAQ</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">High</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Low</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Close</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Volume</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">High</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Low</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Close</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Volume</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Period</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(C$)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(C$)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(C$)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(Shares)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(US$)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(US$)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(US$)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(Shares)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><U>2019</U></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%">December</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">7.84</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">1.40</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">6.15</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">10,754,714</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">6.02</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">1.05</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">4.76</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">50,413,513</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">January</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.26</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.16</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.42</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,737,433</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.82</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.38</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.38</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,177,410</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">February</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.07</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.45</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.71</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,260,826</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.06</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.83</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.02</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16,936,244</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">March</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.81</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.35</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.98</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,982,156</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.85</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.94</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.38</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,768,154</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">April</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.71</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.81</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.34</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,490,898</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.92</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.26</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.65</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,112,601</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">May</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.02</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.02</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.34</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,413,279</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.92</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.44</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.44</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">34,431,369</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">June</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.57</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,300,369</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.36</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.83</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.88</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,959,503</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">July</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.99</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.67</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,450,554</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.24</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.83</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.02</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,743,011</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">August</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.85</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.08</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.27</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,692,002</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.15</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.57</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.76</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,596,435</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">September</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.52</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.28</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,123,822</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.92</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.52</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.69</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,843,143</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">October</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.18</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.24</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.78</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,275,778</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.44</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.68</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.09</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,476,651</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">November</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.69</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.58</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,034,766</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.64</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.96</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.49</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,929,943</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">December 1 to 3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.95</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.27</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,308,735</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.84</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.63</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">5,761,873</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_013"></A>PRIOR
SALES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
as disclosed under this heading, no other Common Shares or securities exchangeable or convertible into Common Shares have been
issued during the twelve month period preceding the date of this Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the twelve month period prior to the date of this Prospectus Supplement, the Corporation has issued:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
                                         aggregate of 8,294,452 Common Shares pursuant to an equity distribution agreement dated
                                         October 25 2018 and prospectus supplements dated October 25, 2018, January 3, 2020 and
                                         March 6, 2020 to a base shelf prospectus dated May 4, 2018 (the &ldquo;<B>2018 Prospectus</B>&rdquo;),
                                         at prices ranging from US$1.10 to US$4.37 per Common Share, with the weighted average
                                         price being US$2.34 per Common Share;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
                                         aggregate of 4,608,046 Common Shares pursuant to the Equity<BR>
                                         Distribution Agreement and a prospectus supplement (the &ldquo;<B>Prior Prospectus Supplement</B>&rdquo;)
                                         dated June 15, 2020 to the Prospectus, at prices ranging from US$1.61 to US$2.69 per
                                         Common Share, with the weighted average price being US$2.10 per Common Share;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
                                         aggregate of 1,054,379 Common Shares pursuant to a purchase agreement dated September
                                         28, 2018 between the Corporation and Lincoln Park Capital Fund and a prospectus supplement
                                         dated September 28, 2018 to the 2018 Prospectus, at prices ranging from US$0.92 to US$1.64
                                         per Common Share, with the weighted average price being US$1.28 per Common Share; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
                                         aggregate of 2,839,202 Common Shares upon exercise of Common Share purchase warrants
                                         at a price of US$0.90 per Common Share;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #010000">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
                                         aggregate of 234,172 Common Shares issued on the vesting of restricted share awards and
                                         performance share awards granted pursuant to its amended and restated incentive share
                                         award plan; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #010000">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
                                         aggregate of 106,787 Common Shares issued on the exercise of stock options granted pursuant
                                         to its amended and restated stock option plan, particulars of which are set forth in
                                         the following table:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Date
of Issue</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Number
of Common Shares Issued</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Price
per Common Share (C$)</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%">January 8, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">1.45</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">January 10, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22,796</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.78</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">January 13, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.45</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">June 4, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,324</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.41</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">October 30, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">41,667</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.45</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">November 2, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.73</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">December 1, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.38</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">December 2, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.38</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Stock
Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the twelve month period preceding the date of this Prospectus Supplement, the Corporation granted stock options pursuant to its
amended and restated stock option plan exercisable for an aggregate of 1,120,000 Common Shares. The particulars of such grants
are set forth in the following table:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Date of Grant</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Options Granted</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price (C$)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%">December 13, 2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">900,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">1.45</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">January 9, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">60,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.23</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">August 1, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">95,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.84</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">September 1, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.27</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">October 14, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.77</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Share
Awards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the twelve month period preceding the date of this Prospectus Supplement, the Corporation granted restricted share awards pursuant
to its amended and restated incentive share award plan which, upon vesting, will entitle the holders thereof to receive up to
an aggregate of 148,399 Common Shares. The particulars of such grants are set forth in the following table:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Date
of Grant</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Number
of Share Awards Granted</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%">January 6, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">6,430</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="background-color: White; width: 1%">&nbsp;</TD>
    <TD STYLE="background-color: White; width: 1%">&nbsp;</TD>
    <TD STYLE="background-color: White; width: 10%">&nbsp;</TD>
    <TD STYLE="background-color: White; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">March 31, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,230</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">June 30, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,343</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">September 30, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,496</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">October 1, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">104,898</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_014"></A>PLAN
OF DISTRIBUTION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have entered into the Equity Distribution Agreement with the Agent under which we may issue and sell from time to time up to US$40,000,000
of our Common Shares through the Agent, as agent. An aggregate of approximately US$9,700,000 of our Common Shares were previously
issued under the Equity Distribution Agreement pursuant to the Prior Prospectus Supplement. Common Shares having an aggregate
Offering amount of up to US$30,300,000 are being offered under this Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sales
of the Common Shares will be made in transactions that are deemed to be &ldquo;at-the-market distributions&rdquo; as defined in
NI 44-102, including sales made directly on the NASDAQ or other existing trading markets in the United States. Subject to the
terms and conditions of the Equity Distribution Agreement and upon delivery of a placement notice from us, the Agent will solicit
offers to purchase our Common Shares directly on the NASDAQ or other existing trading markets in the United States. We will instruct
the Agent as to the number of Common Shares to be sold by them from time to time. No Common Shares will be sold on the TSX or
on other trading markets in Canada as at-the-market distributions. We may instruct the Agent not to the sell Common Shares if
the sales cannot be effected at or above the price designated by us from time to time. We or the Agent may suspend the Offering
of the Common Shares upon notice and subject to other conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
will pay the Agent commissions, in cash, for its services in acting as agent in the sale of our Common Shares. The Agent will
be entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per Common Share sold. Because there is
no minimum offering amount required as a condition to close the Offering, the actual total public offering amount, commissions
and proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse the Agent for certain specified
expenses, including the fees and disbursements of its legal counsel, in an amount not to exceed US$50,000. We estimate that the
total expenses for the Offering, excluding compensation and reimbursements payable to the Agent under the terms of the Equity
Distribution Agreement, will be approximately US$200,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Settlement
for sales of our Common Shares will occur on the second business day following the date on which any sales are made, or on such
other date as is industry practice for regular-way trading, in return for payment of the net proceeds to us. Sales of our Common
Shares as contemplated in this Prospectus will be settled through the facilities of The Depository Trust Company or by such other
means as we and the Agent may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Agent will use its commercially reasonable efforts, consistent with its sales and trading practices, to solicit offers to purchase
the Common Shares under the terms and subject to the conditions set forth in the Equity Distribution Agreement. In connection
with the sale of the Common Shares on our behalf, the Agent will be deemed to be an &ldquo;underwriter&rdquo; within the meaning
of the U.S. Securities Act, and the compensation of the Agent will be deemed to be underwriting commissions or discounts. We have
agreed to provide indemnification and contribution to the Agent against certain civil liabilities, including liabilities under
the U.S. Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
offering of Common Shares pursuant to the Equity Distribution Agreement will terminate upon the earlier of (i) the sale of all
Common Shares subject to the Equity Distribution Agreement, or (ii) termination of the Equity Distribution Agreement as permitted
therein. We and the Agent may each terminate the Equity Distribution Agreement at any time upon ten days&rsquo; prior notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Agent and its affiliates may in the future provide various investment banking, commercial banking and other financial services
for us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation
M, the Agent will not engage in any market making activities involving our Common Shares while the Offering is ongoing under this
Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
underwriter of the Offering, and no person or company acting jointly or in concert with an underwriter, may, in connection with
the distribution under this Prospectus Supplement, enter into any transaction that is intended to stabilize or maintain the market
price of the Common Shares distributed under this Prospectus Supplement, including selling an aggregate number of Common Shares
that would result in the underwriter creating an over-allocation position in the Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The TSX has conditionally approved the
listing of the Common Shares offered by this Prospectus Supplement. Listing is subject to us fulfilling all of the requirements
of the TSX. The Company has provided notice to NASDAQ for the listing of the Common Shares offered hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_015"></A>CERTAIN
CANADIAN FEDERAL INCOME TAX CONSIDERATIONS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following is, as of the date of this Prospectus Supplement, a summary of the principal Canadian federal income tax considerations
under the <I>Income Tax Act </I>(Canada) (&ldquo;<B>Tax Act</B>&rdquo;) and the regulations thereunder (the &ldquo;<B>Regulations</B>&rdquo;)
generally applicable to an investor who acquires as beneficial owner Common Shares pursuant to the Offering and who, for the purposes
of the Tax Act and the Regulations and at all relevant times deals at arm&rsquo;s length with the Corporation and the Agent, is
not affiliated with the Corporation or the Agent, is not exempt from tax under Part I of the Tax Act, and who acquires and holds
the Common Shares, as capital property (a &ldquo;<B>Holder</B>&rdquo;). Generally, the Common Shares will be considered to be
capital property to a Holder provided that the Holder does not hold the Common Shares in the course of carrying on a business
as part of an adventure or concern in the nature of trade.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
summary is generally applicable to a Holder who, at all relevant times, for purposes of the Tax Act: (i) is not, and is not deemed
to be, resident in Canada for the purposes of the Tax Act or any applicable income tax treaty or convention; and (ii) does not
and will not use or hold, and is not and will not be deemed to hold, the Common Shares in connection with carrying on a business
in Canada (a &ldquo;<B>Non-Resident Holder</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Special
rules, which are not discussed in this summary, may apply to certain holders that are insurers carrying on an insurance business
in Canada and elsewhere. Such Holders should consult their own tax advisors with respect to an investment in Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
summary is based upon the current provisions of the Tax Act and the Regulations in force as of the date hereof and counsel&rsquo;s
understanding of the current administrative policies and assessing practices of the Canada Revenue Agency (the &ldquo;<B>CRA</B>&rdquo;)
published in writing by the CRA prior to the date hereof. This summary takes into account all specific proposals to amend the
Tax Act and the Regulations publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof (the
 &ldquo;<B>Tax Proposals</B>&rdquo;) and assumes that the Tax Proposals will be enacted in the form proposed, although no assurance
can be given that the Tax Proposals will be enacted in their current form or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
than the Tax Proposals, this summary does not otherwise take into account or anticipate any changes in law, whether by legislative,
governmental, administrative or judicial decision or action, nor does it take into account or consider any provincial, territorial
or foreign income tax considerations, which considerations may differ significantly from the Canadian federal income tax considerations
discussed in this summary. This summary also does not take into account any change in the administrative policies or assessing
practices of the CRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>This
summary is of a general nature only, is not exhaustive of all possible Canadian federal income tax considerations and is not intended
to be, nor should it be construed to be, legal or tax advice to any particular Holder. Holders should consult their own tax advisors
with respect to their particular circumstances.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Currency</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
purposes of the Tax Act, all amounts relating to the acquisition, holding or disposition of the Common Shares (including dividends,
adjusted cost base and proceeds of disposition) must, to the extent such amounts are not in Canadian dollars, be converted into
Canadian dollars based on an exchange rate determined in accordance with the Tax Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividends
paid or credited or deemed to be paid or credited on the Common Shares to a Non-Resident Holder by the Corporation are subject
to Canadian withholding tax at the rate of 25% on the gross amount of the dividend, unless such rate is reduced by the terms of
an applicable tax treaty. For example, under the Canada-United States Tax Convention (1980), as amended (the &ldquo;<B>Treaty</B>&rdquo;),
the rate of withholding tax on dividends paid or credited to a Non-Resident Holder who is a beneficial owner of dividends and
who is a resident of the United States for purposes of the Treaty and who is entitled to the benefits of the Treaty (a &ldquo;<B>US
Holder</B>&rdquo;) is generally limited to 15% of the gross amount of the dividend. <B>Non-Resident Holders are urged to consult
their own tax advisors to determine their entitlement to relief under an applicable income tax treaty.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Dispositions
of Common Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
a disposition (or a deemed disposition) of a Common Share (other than to the Corporation unless purchased by the Corporation in
the open market in the manner in which shares are normally purchased by any member of the public in the open market), a Non-Resident
Holder generally will realize a capital gain (or a capital loss) equal to the amount by which the proceeds of disposition of such
Common Shares, net of any reasonable costs of disposition, are greater (or are less) than the adjusted cost base of such Common
Share to the Non-Resident Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
Non-Resident Holder generally will not be subject to tax under the Tax Act in respect of a capital gain realized on the disposition
or deemed disposition of a Common Share, unless the Common Share constitutes &ldquo;taxable Canadian property&rdquo; and is not
 &ldquo;treaty-protected property&rdquo; (each as defined under the Tax Act) of the Non-Resident Holder at the time of disposition</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Provided
the Common Shares are listed on a &ldquo;designated stock exchange&rdquo;, as defined in the Tax Act (which currently includes
the NASDAQ and TSX), at the time of disposition, the Common Shares generally will not constitute taxable Canadian property of
a Non-Resident Holder at that time, unless at any time during the 60 month period immediately preceding the disposition the following
two conditions are met concurrently: (i) one or any combination of (a) the Non-Resident Holder, (b) persons with whom the Non-Resident
Holder did not deal at arm&rsquo;s length, and (c) partnerships in which the Non-Resident Holder or a person with whom the Non-Resident
Holder did not deal at arm&rsquo;s length held a membership interest directly or indirectly through one or more partnerships,
owned 25% or more of the issued shares of any class or series of shares of the Corporation; and (ii) more than 50% of the fair
market value of such shares was derived directly or indirectly from one or any combination of (a) real or immovable property situated
in Canada, (b) &ldquo;Canadian resource properties&rdquo; (as defined in the Tax Act), (c) &ldquo;timber resource properties&rdquo;
(as defined in the Tax Act) or (d) an option in respect of, an interest in, or for civil law a right in any of the foregoing property,
whether or not such property exists. Notwithstanding the foregoing, a Common Share may otherwise be deemed to be taxable Canadian
property to a Non-Resident Holder for purposes of the Tax Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Non-Resident
Holders whose Common Shares may be taxable Canadian property should consult their own tax advisors.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_016"></A>MATERIAL
UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following is a general summary of certain material U.S. federal income tax considerations applicable to a U.S. Holder (as defined
below) arising from and relating to the acquisition, ownership, and disposition of Common Shares acquired pursuant to this Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S.
federal income tax considerations that may apply to a U.S. Holder arising from and relating to the acquisition, ownership, and
disposition of Common Shares. In addition, this summary does not take into account the individual facts and circumstances of any
particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder, including, without limitation,
specific tax consequences to a U.S. Holder under an applicable income tax treaty. Accordingly, this summary is not intended to
be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder. This summary does
not address the U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state
and local, and non-U.S. tax consequences to U.S. Holders of the acquisition, ownership, and disposition of Common Shares. In addition,
except as specifically set forth below, this summary does not discuss applicable tax reporting requirements. Each prospective
U.S. Holder should consult its own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal net
investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition,
ownership and disposition of Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
legal opinion from U.S. legal counsel or ruling from the Internal Revenue Service (the &ldquo;<B>IRS</B>&rdquo;) has been requested,
or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common
Shares. This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and
contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject
to various interpretations, the IRS and the U.S. courts could disagree with one or more of the conclusions described in this summary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Scope
of this Summary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Authorities</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
summary is based on the Internal Revenue Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;), Treasury Regulations (whether
final, temporary, or proposed), published rulings of the IRS, published administrative positions of the IRS, the Convention Between
Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended
(the &ldquo;<B>Canada-U.S. Tax Convention</B>&rdquo;), and U.S. court decisions that are applicable, and, in each case, as in
effect and available, as of the date of this document. Any of the authorities on which this summary is based could be changed
in a material and adverse manner at any time, and any such change could be applied retroactively. This summary does not discuss
the potential effects, whether adverse or beneficial, of any proposed legislation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>U.S.
Holders</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
purposes of this summary, the term &ldquo;<B>U.S. Holder</B>&rdquo; means a beneficial owner of Common Shares acquired pursuant
to this Offering that is for U.S. federal income tax purposes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an individual who is a citizen or resident of the United States;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) organized
under the laws of the United States, any state thereof or the District of Columbia;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a trust that (1) is subject to the primary supervision of a court within the U.S. and the control
of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable Treasury Regulations
to be treated as a U.S. person.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>U.S.
Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
summary does not address the U.S. federal income tax considerations applicable to U.S. Holders that are subject to special provisions
under the Code, including, but not limited to, U.S. Holders that: (a) are tax-exempt organizations, qualified retirement plans,
individual retirement accounts, or other tax-deferred accounts; (b) are financial institutions, underwriters, insurance companies,
real estate investment trusts, or regulated investment companies; (c) are broker-dealers, dealers, or traders in securities or
currencies that elect to apply a mark-to-market accounting method; (d) have a &ldquo;functional currency&rdquo; other than the
U.S. dollar; (e) own Common Shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other
arrangement involving more than one position; (f) acquire Common Shares in connection with the exercise of employee stock options
or otherwise as compensation for services; (g) hold Common Shares other than as a capital asset within the meaning of Section
1221 of the Code (generally, property held for investment purposes); (h) are required to accelerate the recognition of any item
of gross income with respect to Common Shares as a result of such income being recognized on an applicable financial statement;
or (i) own, have owned or will own (directly, indirectly, or by attribution) 10% or more of the total combined voting power or
value of the outstanding shares of the Corporation. This summary also does not address the U.S. federal income tax considerations
applicable to U.S. Holders who are: (a) U.S. expatriates or former long-term residents of the U.S.; (b) persons that have been,
are, or will be a resident or deemed to be a resident in Canada for purposes of the Tax Act; (c) persons that use or hold, will
use or hold, or that are or will be deemed to use or hold Common Shares in connection with carrying on a business in Canada; (d)
persons whose Common Shares constitute &ldquo;taxable Canadian property&rdquo; under the Tax Act; or (e) persons that have a permanent
establishment in Canada for the purposes of the Canada-U.S. Tax Convention. U.S. Holders that are subject to special provisions
under the Code, including, but not limited to, U.S. Holders described immediately above, should consult their own tax advisors
regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift,
U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an entity or arrangement that is classified as a partnership (or other &ldquo;pass-through&rdquo; entity) for U.S. federal income
tax purposes holds Common Shares, the U.S. federal income tax consequences to such entity or arrangement and the partners (or
other owners or participants) of such entity or arrangement generally will depend on the activities of the entity or arrangement
and the status of such partners (or owners or participants). This summary does not address the tax consequences to any such partner
(or owner or participants). Partners (or other owners or participants) of entities or arrangements that are classified as partnerships
or as &ldquo;pass-through&rdquo; entities for U.S. federal income tax purposes should consult their own tax advisors regarding
the U.S. federal income tax consequences arising from and relating to the acquisition, ownership, and disposition of Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Passive
Foreign Investment Company Rules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>PFIC
Status of the Corporation</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the Corporation were to constitute a &ldquo;passive foreign investment company&rdquo; under the meaning of Section 1297 of the
Code (a &ldquo;<B>PFIC</B>&rdquo;, as defined below) for any year during a U.S. Holder&rsquo;s holding period, then certain potentially
adverse rules would affect the U.S. federal income tax consequences to a U.S. Holder as a result of the acquisition, ownership
and disposition of Common Shares. The Corporation believes that it was classified as a PFIC during the tax year ended December
31, 2019, and based on current business plans and financial expectations, the Corporation expects that it will be a PFIC for the
current tax year and may be a PFIC in future tax years. No opinion of legal counsel or ruling from the IRS concerning the status
of the Corporation as a PFIC has been obtained or is currently planned to be requested. The determination of whether any corporation
was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are
subject to differing interpretations. In addition, whether any corporation will be a PFIC for any tax year depends on the assets
and income of such corporation over the course of each such tax year and, as a result, cannot be predicted with certainty as of
the date of this document. Accordingly, there can be no assurance that the IRS will not challenge any determination made by the
Corporation (or any subsidiary of the Corporation) concerning its PFIC status. Each U.S. Holder should consult its own tax advisors
regarding the PFIC status of the Corporation and each subsidiary of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
any year in which the Corporation is classified as a PFIC, a U.S. Holder will be required to file an annual report with the IRS
containing such information as Treasury Regulations and/or other IRS guidance may require. In addition to penalties, a failure
to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax. U.S.
Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules,
including the requirement to file an IRS Form 8621 annually.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Corporation generally will be a PFIC if, for a tax year, (a) 75% or more of the gross income of the Corporation is passive income
(the &ldquo;<B>PFIC income test</B>&rdquo;) or (b) 50% or more of the value of the Corporation&rsquo;s assets either produce passive
income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets
(the &ldquo;<B>PFIC asset test</B>&rdquo;). &ldquo;Gross income&rdquo; generally includes all sales revenues less the cost of
goods sold, plus income from investments and from incidental or outside operations or sources, and &ldquo;passive income&rdquo;
generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities,
and certain gains from commodities transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
purposes of the PFIC income test and PFIC asset test described above, if the Corporation owns, directly or indirectly, 25% or
more of the total value of the outstanding shares of another corporation, the Corporation will be treated as if it (a) held a
proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such
other corporation. In addition, for purposes of the PFIC income test and PFIC asset test described above, and assuming certain
other requirements are met, &ldquo;passive income&rdquo; does not include certain interest, dividends, rents, or royalties that
are received or accrued by the Corporation from certain &ldquo;related persons&rdquo; (as defined in Section 954(d)(3) of the
Code) also organized in Canada, to the extent such items are properly allocable to the income of such related person that is not
passive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
certain attribution rules, if the Corporation is a PFIC, U.S. Holders will generally be deemed to own their proportionate share
of the Corporation&rsquo;s direct or indirect equity interest in any company that is also a PFIC (a &lsquo;&lsquo;<B>Subsidiary
PFIC</B>&rsquo;&rsquo;), and will generally be subject to U.S. federal income tax on their proportionate share of (a) any &ldquo;excess
distributions,&rdquo; as described below, on the stock of a Subsidiary PFIC and (b) a disposition or deemed disposition of the
stock of a Subsidiary PFIC by the Corporation or another Subsidiary PFIC, both as if such U.S. Holders directly held the shares
of such Subsidiary PFIC. In addition, U.S. Holders may be subject to U.S. federal income tax on any indirect gain realized on
the stock of a Subsidiary PFIC on the sale or disposition of Common Shares. Accordingly, U.S. Holders should be aware that they
could be subject to tax under the PFIC rules even if no distributions are received and no redemptions or other dispositions of
Common Shares are made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Default
PFIC Rules Under Section 1291 of the Code</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the Corporation is a PFIC for any tax year during which a U.S. Holder owns Common Shares, the U.S. federal income tax consequences
to such U.S. Holder of the acquisition, ownership, and disposition of Common Shares will depend on whether and when such U.S.
Holder makes an election to treat the Corporation and each Subsidiary PFIC, if any, as a &ldquo;qualified electing fund&rdquo;
or &ldquo;QEF&rdquo; under Section 1295 of the Code (a &ldquo;<B>QEF Election</B>&rdquo;) or makes a mark-to-market election under
Section 1296 of the Code (a &ldquo;<B>Mark-to-Market Election</B>&rdquo;). A U.S. Holder that does not make either a QEF Election
or a Mark-to-Market Election will be referred to in this summary as a &ldquo;<B>Non-Electing U.S. Holder</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
Non-Electing U.S. Holder will be subject to the rules of Section 1291 of the Code (described below) with respect to (a) any gain
recognized on the sale or other taxable disposition of Common Shares and (b) any &ldquo;excess distribution&rdquo; received on
the Common Shares. A distribution generally will be an &ldquo;excess distribution&rdquo; to the extent that such distribution
(together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during
the three preceding tax years (or during a U.S. Holder&rsquo;s holding period for the Common Shares, if shorter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of Common Shares (including an indirect
disposition of the stock of any Subsidiary PFIC), and any &ldquo;excess distribution&rdquo; received on Common Shares or with
respect to the stock of a Subsidiary PFIC, must be ratably allocated to each day in a Non-Electing U.S. Holder&rsquo;s holding
period for the respective Common Shares. The amount of any such gain or excess distribution allocated to the tax year of disposition
or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income
(and not eligible for certain preferred rates). The amounts allocated to any other tax year would be subject to U.S. federal income
tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax
liability for each such year, calculated as if such tax liability had been due in each such year. A Non-Electing U.S. Holder that
is not a corporation must treat any such interest paid as &ldquo;personal interest,&rdquo; which is not deductible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the Corporation is a PFIC for any tax year during which a Non-Electing U.S. Holder holds Common Shares, the Corporation will continue
to be treated as a PFIC with respect to such Non-Electing U.S. Holder, regardless of whether the Corporation ceases to be a PFIC
in one or more subsequent tax years. A Non-Electing U.S. Holder may terminate this deemed PFIC status by electing to recognize
gain (which will be taxed under the rules of Section 1291 of the Code discussed above), but not loss, as if such Common Shares
were sold on the last day of the last tax year for which the Corporation was a PFIC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>QEF
Election</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
U.S. Holder that makes a timely and effective QEF Election for the first tax year in which the holding period of its Common Shares
begins generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its Common Shares.
A U.S. Holder that makes a timely and effective QEF Election will be subject to U.S. federal income tax on such U.S. Holder&rsquo;s
pro rata share of (a) the net capital gain of the Corporation, which will be taxed as long-term capital gain to such U.S. Holder,
and (b) the ordinary earnings of the Corporation, which will be taxed as ordinary income to such U.S. Holder. Generally, &ldquo;net
capital gain&rdquo; is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and &ldquo;ordinary
earnings&rdquo; are the excess of (a) &ldquo;earnings and profits&rdquo; over (b) net capital gain. A U.S. Holder that makes a
QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which the Corporation is a PFIC,
regardless of whether such amounts are actually distributed to such U.S. Holder by the Corporation. However, for any tax year
in which the Corporation is a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election would not have any
income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S.
Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject
to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as &ldquo;personal interest,&rdquo;
which is not deductible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
U.S. Holder that makes a timely and effective QEF Election with respect to the Corporation generally (a) may receive a tax-free
distribution from the Corporation to the extent that such distribution represents &ldquo;earnings and profits&rdquo; of the Corporation
that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder&rsquo;s
tax basis in the Common Shares to reflect the amount included in income or allowed as a tax-free distribution because of such
QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or
other taxable disposition of Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether
such QEF Election is timely. A QEF Election will be treated as &ldquo;timely&rdquo; if such QEF Election is made for the first
year in the U.S. Holder&rsquo;s holding period for the Common Shares in which the Corporation was a PFIC. A U.S. Holder may make
a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income
tax return for such year. If a U.S. Holder does not make a timely and effective QEF Election for the first year in the U.S. Holder&rsquo;s
holding period for the Common Shares, the U.S. Holder may still be able to make a timely and effective QEF Election in a subsequent
year if such U.S. Holder meets certain requirements and makes a &ldquo;purging&rdquo; election to recognize gain (which will be
taxed under the rules of Section 1291 of the Code discussed above) as if such Common Shares were sold for their fair market value
on the day the QEF Election is effective. If a U.S. Holder makes a QEF Election but does not make a &ldquo;purging&rdquo; election
to recognize gain as discussed in the preceding sentence, then such U.S. Holder shall be subject to the QEF Election rules and
shall continue to be subject to tax under the rules of Section 1291 discussed above with respect to its Common Shares. If a U.S.
Holder owns PFIC stock indirectly through another PFIC, separate QEF Elections must be made for the PFIC in which the U.S. Holder
is a direct shareholder and the Subsidiary PFIC for the QEF rules to apply to both PFICs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
QEF Election will apply to the tax year for which such QEF Election is timely made and to all subsequent tax years, unless such
QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF
Election and, in a subsequent tax year, the Corporation ceases to be a PFIC, the QEF Election will remain in effect (although
it will not be applicable) during those tax years in which the Corporation is not a PFIC. Accordingly, if the Corporation becomes
a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules
described above during any subsequent tax year in which the Corporation qualifies as a PFIC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Corporation: (a) will make available to U.S. Holders, upon their written request, information as to its status as a PFIC and the
PFIC status of any subsidiary in which the Corporation owns more than 50% of such subsidiary&rsquo;s total aggregate voting power
and (b) for each year in which the Corporation is a PFIC, provide to a U.S. Holder, upon written request, such information and
documentation that a U.S. Holder making a QEF Election with respect to the Corporation and such more than 50% owned subsidiary
which constitutes a PFIC is reasonably required to obtain for U.S. federal income tax purposes. The Corporation may elect to provide
such information on its website. With respect to any Subsidiary PFIC in which the Corporation owns 50% or less of the aggregate
voting power, upon the written request of a U.S. Holder acquiring Common Shares, the Corporation will request that such Subsidiary
PFIC provide such U.S. Holder with the information that such U.S. Holder requires to report under the QEF rules; provided, however,
the Corporation can provide no assurances that such Subsidiary PFIC will provide such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
U.S. Holder makes a QEF Election by attaching a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely
filed United States federal income tax return. However, if the Corporation does not provide the required information with regard
to the Corporation or any of its Subsidiary PFICs, U.S. Holders will not be able to make a QEF Election for such entity and will
continue to be subject to the rules of Section 1291 of the Code discussed above that apply to Non-Electing U.S. Holders with respect
to the taxation of gains and excess distributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Mark-to-Market
Election</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
U.S. Holder may make a Mark-to-Market Election only if the Common Shares are marketable stock. The Common Shares generally will
be &ldquo;marketable stock&rdquo; if the Common Shares are regularly traded on (a) a national securities exchange that is registered
with the Securities and Exchange Commission, (b) the national market system established pursuant to section 11A of the U.S. Exchange
Act, or (c) a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which
the market is located, provided that (i) such foreign exchange has trading volume, listing, financial disclosure, and surveillance
requirements, and meets other requirements, and the laws of the country in which such foreign exchange is located, together with
the rules of such foreign exchange, ensure that such requirements are actually enforced and (ii) the rules of such foreign exchange
effectively promote active trading of listed stocks. If such stock is traded on such a qualified exchange or other market, such
stock generally will be &ldquo;regularly traded&rdquo; for any calendar year during which such stock is traded, other than in
de minimis quantities, on at least 15 days during each calendar quarter. Provided that the Common Shares are &ldquo;regularly
traded&rdquo; as described in the preceding sentence, the Common Shares are expected to be marketable stock. However, each U.S.
Holder should consult its own tax advisor in this matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
U.S. Holder that makes a Mark-to-Market Election with respect to its Common Shares generally will not be subject to the rules
of Section 1291 of the Code discussed above with respect to such Common Shares. However, if a U.S. Holder does not make a Mark-to-Market
Election beginning in the first tax year of such U.S. Holder&rsquo;s holding period for the Common Shares for which the Corporation
is a PFIC and such U.S. Holder has not made a timely QEF Election, the rules of Section&nbsp;1291 of the Code discussed above
will apply to certain dispositions of, and distributions on, the Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which the Corporation is
a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the Common Shares, as of the close of such tax
year over (b) such U.S. Holder&rsquo;s adjusted tax basis in such Common Shares. A U.S. Holder that makes a Mark-to-Market Election
will be allowed a deduction in an amount equal to the excess, if any, of (a) such U.S. Holder&rsquo;s adjusted tax basis in the
Common Shares, over (b) the fair market value of such Common Shares (but only to the extent of the net amount of previously included
income as a result of the Mark-to-Market Election for prior tax years).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
U.S. Holder that makes a Mark-to-Market Election generally also will adjust such U.S. Holder&rsquo;s tax basis in the Common Shares
to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election. In addition,
upon a sale or other taxable disposition of Common Shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary
income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market
Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax
years). Losses that exceed this limitation are subject to the rules generally applicable to losses provided in the Code and Treasury
Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
U.S. Holder makes a Mark-to-Market Election by attaching a completed IRS Form 8621 to a timely filed United States federal income
tax return. A Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent
tax year, unless the Common Shares cease to be &ldquo;marketable stock&rdquo; or the IRS consents to revocation of such election.
Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a Mark-to-Market
Election.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although
a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to the Common Shares, no such election may be made
with respect to the stock of any Subsidiary PFIC that a U.S. Holder is treated as owning, because such stock is not marketable.
Hence, the Mark-to-Market Election will not be effective to avoid the application of the default rules of Section 1291 of the
Code described above with respect to deemed dispositions of Subsidiary PFIC stock or excess distributions from a Subsidiary PFIC
to its shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Other
PFIC Rules</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
Section 1291(f) of the Code, the IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause
a U.S. Holder that had not made a timely QEF Election to recognize gain (but not loss) upon certain transfers of Common Shares
that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate reorganizations). However, the specific
U.S. federal income tax consequences to a U.S. Holder may vary based on the manner in which Common Shares are transferred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Certain
additional adverse rules may apply with respect to a U.S. Holder if the Corporation is a PFIC, regardless of whether such U.S.
Holder makes a QEF Election. For example, under Section 1298(b)(6) of the Code, a U.S. Holder that uses Common Shares as security
for a loan will, except as may be provided in Treasury Regulations, be treated as having made a taxable disposition of such Common
Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Special
rules also apply to the amount of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC. Subject to such
special rules, foreign taxes paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the
foreign tax credit. The rules relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated,
and a U.S. Holder should consult with its own tax advisors regarding the availability of the foreign tax credit with respect to
distributions by a PFIC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
PFIC rules are complex, and each U.S. Holder should consult its own tax advisors regarding the PFIC rules and how the PFIC rules
may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>General
Rules Applicable to the Ownership and Disposition of Common Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following discussion describes the general rules applicable to the ownership and disposition of the Common Shares but is subject
in its entirety to the special rules described above under the heading &ldquo;Passive Foreign Investment Company Rules.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Distributions
on Common Shares</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
U.S. Holder that receives a distribution, including a constructive distribution, with respect to a Common Share will be required
to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld
from such distribution) to the extent of the current and accumulated &ldquo;earnings and profits&rdquo; of the Corporation, as
computed for U.S. federal income tax purposes. A dividend generally will be taxed to a U.S. Holder at ordinary income tax rates
if the Corporation is a PFIC for the tax year of such distribution or the preceding tax year. To the extent that a distribution
exceeds the current and accumulated &ldquo;earnings and profits&rdquo; of the Corporation, such distribution will be treated first
as a tax-free return of capital to the extent of a U.S. Holder&rsquo;s tax basis in the Common Shares and thereafter as gain from
the sale or exchange of such Common Shares. (See &ldquo;<I>Sale or Other Taxable Disposition of Common Shares</I>&rdquo; below).
However, the Corporation may not maintain the calculations of its earnings and profits in accordance with U.S. federal income
tax principles, and each U.S. Holder may have to assume that any distribution by the Corporation with respect to the Common Shares
will constitute ordinary dividend income. Dividends received on Common Shares by corporate U.S. Holders generally will not be
eligible for the &ldquo;dividends received deduction.&rdquo; Subject to applicable limitations and provided the Corporation is
eligible for the benefits of the Canada-U.S. Tax Convention or the Common Shares are readily tradable on a United States securities
market, dividends paid by the Corporation to non-corporate U.S. Holders, including individuals, generally will be eligible for
the preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions
are satisfied, including that the Corporation not be classified as a PFIC in the tax year of distribution or in the preceding
tax year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisors regarding the application of
such rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Sale
or Other Taxable Disposition of Common Shares</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
the sale or other taxable disposition of Common Shares, a U.S. Holder generally will recognize capital gain or loss in an amount
equal to the difference between the U.S. dollar value of cash received plus the fair market value of any property received and
such U.S. Holder&rsquo;s tax basis in such Common Shares sold or otherwise disposed of. A U.S. Holder&rsquo;s tax basis in Common
Shares generally will be such holder&rsquo;s U.S. dollar cost for such Common Shares. Gain or loss recognized on such sale or
other disposition generally will be long-term capital gain or loss if, at the time of the sale or other disposition, the Common
Shares have been held for more than one year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferential
tax rates currently apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust. There are currently
no preferential tax rates for long-term capital gain of a U.S. Holder that is a corporation. Deductions for capital losses are
subject to significant limitations under the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Additional
Considerations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Receipt
of Foreign Currency</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
amount of any distribution paid to a U.S. Holder in foreign currency, or on the sale, exchange or other taxable disposition of
Common Shares, generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable
on the date of receipt (regardless of whether such foreign currency is converted into U.S. dollars at that time). A U.S. Holder
will have a basis in the foreign currency equal to its U.S. dollar value on the date of receipt. Any U.S. Holder who converts
or otherwise disposes of the foreign currency after the date of receipt may have a foreign currency exchange gain or loss that
would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes.
Different rules apply to U.S. Holders who use the accrual method of tax accounting. Each U.S. Holder should consult its own U.S.
tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Foreign
Tax Credit</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject
to the PFIC rules discussed above, a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with
respect to dividends paid on the Common Shares generally will be entitled, at the election of such U.S. Holder, to receive either
a deduction or a credit for such Canadian income tax. Generally, a credit will reduce a U.S. Holder&rsquo;s U.S. federal income
tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Holder&rsquo;s income that is subject to U.S.
federal income tax. This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through
withholding) by a U.S. Holder during a year. The foreign tax credit rules are complex and involve the application of rules that
depend on a U.S. Holder&rsquo;s particular circumstances. Accordingly, each U.S. Holder should consult its own U.S. tax advisors
regarding the foreign tax credit rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Backup
Withholding and Information Reporting</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
U.S. federal income tax law, certain categories of U.S. Holders must file information returns with respect to their investment
in, or involvement in, a foreign corporation. For example, U.S. return disclosure obligations (and related penalties) are imposed
on individuals who are U.S. Holders that hold certain specified foreign financial assets in excess of certain thresholds. The
definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions,
but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any
financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest
in a foreign entity. U.S. Holders may be subject to these reporting requirements unless their Common Shares are held in an account
at certain financial institutions. Penalties for failure to file certain of these information returns are substantial. U.S. Holders
should consult with their own tax advisors regarding the requirements of filing information returns, including the requirement
to file an IRS Form 8938.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Payments
made within the U.S., or by a U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable
disposition of, Common Shares will generally be subject to information reporting and backup withholding tax if a U.S. Holder (a)
fails to furnish such U.S. Holder&rsquo;s correct U.S. taxpayer identification number (generally on Form W-9), (b) furnishes an
incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously failed to properly
report items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that such U.S. Holder has furnished
its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup
withholding tax. However, certain exempt persons generally are excluded from these information reporting and backup withholding
rules. Backup withholding is not an additional tax. Any amounts withheld under the U.S. backup withholding tax rules will be allowed
as a credit against a U.S. Holder&rsquo;s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder
furnishes required information to the IRS in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
discussion of reporting requirements set forth above is not intended to constitute a complete description of all reporting requirements
that may apply to a U.S. Holder. A failure to satisfy certain reporting requirements may result in an extension of the time period
during which the IRS can assess a tax and, under certain circumstances, such an extension may apply to assessments of amounts
unrelated to any unsatisfied reporting requirement. Each U.S. Holder should consult its own tax advisors regarding the information
reporting and backup withholding rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>THE
ABOVE SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO U.S. HOLDERS WITH RESPECT
TO THE ACQUISITION, OWNERSHIP, AND DISPOSITION OF COMMON SHARES. U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE
TAX CONSIDERATIONS APPLICABLE TO THEM IN THEIR OWN PARTICULAR CIRCUMSTANCES.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_017"></A>STATUTORY
RIGHTS OF WITHDRAWAL AND RESCISSION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
legislation in some provinces and territories of Canada provides purchasers of securities with the right to withdraw from an agreement
to purchase securities and with remedies for rescission or, in some jurisdictions, revisions of the price, or damages if the prospectus,
prospectus supplement, and any amendment relating to securities purchased by a purchaser are not sent or delivered to the purchaser.
However, purchasers of Common Shares distributed under an at-the-market distribution by Oncolytics do not have the right to withdraw
from an agreement to purchase the Common Shares and do not have remedies of rescission or, in some jurisdictions, revisions of
the price, or damages for non-delivery of the prospectus, prospectus supplement, and any amendment relating to the Common Shares
purchased by such purchaser because the prospectus, prospectus supplement, and any amendment relating to the Common Shares purchased
by such purchaser will not be sent or delivered, as permitted under Part 9 of National Instrument 44-102 - <I>Shelf Distributions</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
legislation in some provinces and territories of Canada further provides purchasers with remedies for rescission or, in some jurisdictions,
revisions of the price or damages if the prospectus, prospectus supplement, and any amendment relating to securities purchased
by a purchaser contains a misrepresentation. Those remedies must be exercised by the purchaser within the time limit prescribed
by securities legislation. Any remedies under securities legislation that a purchaser of Common Shares distributed under an at-the-market
distribution by Oncolytics may have against Oncolytics or its agents for rescission or, in some jurisdictions, revisions of the
price, or damages if the prospectus, prospectus supplement, and any amendment relating to securities purchased by a purchaser
contain a misrepresentation will remain unaffected by the non-delivery of the prospectus referred to above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
purchaser should refer to applicable securities legislation for the particulars of these rights and should consult a legal adviser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
foregoing statements supersede the information contained in the Prospectus under the heading &ldquo;<I>Statutory Rights of Withdrawal
and Rescission</I>&rdquo; solely as it relates to the Common Shares being offered by this Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_018"></A>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Corporation has filed with the SEC a registration statement on Form F-10 relating to, among other securities, the Common Shares.
This Prospectus Supplement and the Prospectus, both of which constitute a part of the registration statement, do not contain all
of the information contained in the registration statement, certain items of which are contained in the exhibits to the registration
statement as permitted by the rules and regulations of the SEC. See &ldquo;<I>Documents Filed as Part of the Registration Statement</I>&rdquo;
in this Prospectus Supplement and the Prospectus. Statements contained in this Prospectus Supplement, the Prospectus or a document
incorporated by reference in the Prospectus about the contents of any contract, agreement or other documents referred to are not
necessarily complete, and in each instance you should refer to the exhibits to the registration statement for a more complete
description of the matter involved. The registration statement, and the items of information omitted from this Prospectus Supplement
and the Prospectus but contained in the registration statement, will be available on EDGAR (<U>www.sec.gov/edgar.shtml</U>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Corporation is subject to the information requirements of the U.S.&nbsp;Exchange Act and applicable Canadian securities legislation
and, in accordance therewith, files and furnishes annual and quarterly financial information and material change reports, business
acquisition reports and other material with the securities commission or similar regulatory authority in each of the provinces
of Canada and with the SEC. Under MJDS adopted by the United States and Canada, documents and other information that the Corporation
files with the SEC may be prepared in accordance with the disclosure requirements of Canada, which are different from those of
the United States. As a foreign private issuer within the meaning of rules made under the U.S.&nbsp;Exchange Act, the Corporation
is exempt from the rules under the U.S.&nbsp;Exchange Act prescribing the furnishing and content of proxy statements, and the
Corporation&rsquo;s officers, directors and principal shareholders are exempt from the reporting and shortswing profit recovery
provisions contained in Section&nbsp;16 of the U.S.&nbsp;Exchange Act. In addition, the Corporation is not required to publish
financial statements as promptly as United States companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
may read any document that the Corporation has filed with the SEC on EDGAR at www.sec.gov/edgar.shtml. You may read and download
any public document that the Corporation has filed with the Canadian securities regulatory authorities under the Corporation&rsquo;s
profile on SEDAR (<U>www.sedar.com</U>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_019"></A>LEGAL
MATTERS AND INTEREST OF EXPERTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
auditors of the Corporation are Ernst &amp; Young LLP, Chartered Accountants, Calgary City Centre, 2200, 215 &ndash; 2<SUP>nd
</SUP>Street S.W., Calgary, Alberta, T2P 1M4. Ernst &amp; Young LLP is independent of the Corporation in accordance with the Rules
of Professional Conduct as outlined by the Chartered Professional Accountants of Alberta. Ernst &amp; Young LLP is registered
with the U.S. Public Corporation Accounting Oversight Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Certain
legal matters relating to the Offering will be passed upon on our behalf by McCarthy T&eacute;trault LLP with respect to certain
Canadian legal matters and by Dorsey &amp; Whitney LLP with respect to certain U.S. legal matters and on behalf of the Agent by
Goodwin Procter LLP with respect to certain U.S. legal matters. As at the date hereof, the partners and associates of each of
McCarthy T&eacute;trault LLP beneficially own, directly or indirectly, less than 1% of the Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="s_020"></A>AGENT
FOR SERVICE OF PROCESS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Messrs.
Wayne Pisano and Leonard Kruimer and Drs. William G. Rice and Bernd R. Seizinger are directors of the Corporation who reside outside
of Canada. Messrs. Pisano and Kruimer and Drs. Rice and Seizinger have appointed the Corporation, at its principal place of business,
as agent for service of process. Purchasers are advised that it may not be possible for investors to enforce judgments obtained
in Canada against any person that resides outside of Canada, even if the party has appointed an agent for service of process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>BASE
SHELF PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>JUNE 12, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 105px; width: 240px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cdn.$150,000,000</P>

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subscription Receipts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Biotech Inc. (the &ldquo;<B>Corporation</B>&rdquo;,
 &ldquo;<B>Oncolytics</B>&rdquo;, &ldquo;<B>we</B>&rdquo;, &ldquo;<B>our</B>&rdquo; or &ldquo;<B>us</B>&rdquo;) may from time to
time offer and issue the following securities: (i) common shares in the capital of the Corporation (&ldquo;<B>Common Shares</B>&rdquo;);
(ii) subscription receipts of the Corporation exchangeable for Common Shares and/or other securities of the Corporation (&ldquo;<B>Subscription
Receipts</B>&rdquo;); (iii) warrants exercisable to acquire Common Shares and/or other securities of the Corporation (&ldquo;<B>Warrants</B>&rdquo;);
and (iv) securities comprised of more than one of Common Shares, Subscription Receipts and/or Warrants offered together as a unit
(&ldquo;<B>Units</B>&rdquo;), or any combination thereof, up to an aggregate offering price of $150,000,000 (or the equivalent
thereof, at the date of issue, in any other currency or currencies, as the case may be) at any time during the 25-month period
that this short form base shelf prospectus (including any amendments hereto, the &ldquo;<B>Prospectus</B>&rdquo;) remains valid.
The Common Shares, Subscription Receipts, Warrants and Units (collectively, the &ldquo;<B>Securities</B>&rdquo;) offered hereby
may be offered separately or together, in separate series, in amounts, at prices and on terms to be set forth in one or more prospectus
supplements (collectively or individually, as the case may be, &ldquo;<B>Prospectus Supplements</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The specific terms of any offering of Securities
will be set forth in the applicable Prospectus Supplement and may include, without limitation, where applicable: (i) in the case
of Common Shares, the number of Common Shares being offered, the offering price (in the event the offering is a fixed price distribution),
the manner of determining the offering price(s) (in the event the offering is not a fixed price distribution) and any other specific
terms; (ii) in the case of Subscription Receipts, the number of Subscription Receipts being offered, the offering price, the terms,
conditions and procedures for the exchange of the Subscription Receipts into or for Common Shares and/or other securities of the
Corporation and any other specific terms; (iii) in the case of Warrants, the number of such Warrants offered, the offering price,
the terms, conditions and procedures for the exercise of such Warrants into or for Common Shares and/or other securities of the
Corporation and any other specific terms; and (iv) in the case of Units, the number of Units being offered, the offering price,
the terms of the Common Shares, Subscription Receipts and/or Warrants, as the case may be, underlying the Units, and any other
specific terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>An investment in Securities involves
significant risks that should be carefully considered by prospective investors before purchasing Securities. The risks outlined
in this Prospectus and in the documents incorporated by reference herein, including the applicable Prospectus Supplement, should
be carefully reviewed and considered by prospective investors in connection with any investment in Securities. See &ldquo;<I>Risk
Factors</I>&rdquo;. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This offering is made by a Canadian
issuer that is permitted, under a multijurisdictional disclosure system adopted by the United States and Canada (&ldquo;MJDS&rdquo;),
to prepare this Prospectus in accordance with Canadian disclosure requirements. Prospective investors in the United States should
be aware that such requirements are different from those of the United States. Financial statements included or incorporated by
reference herein have been prepared in accordance with International Financial Reporting Standards (&ldquo;IFRS&rdquo;) as issued
by the International Accounting Standards Board (&ldquo;IASB&rdquo;) and may not be comparable to financial statements of United
States companies. Such financial statements are subject to Canadian generally accepted auditing standards and auditor independence
standards, in addition to the standards of the Public Company Accounting Oversight Board (United States) and the United States
Securities and Exchange Commission (&ldquo;SEC&rdquo;) independence standards.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Prospective
investors should be aware that the acquisition of the Securities described herein may have tax consequences both in the United
States and in Canada. This Prospectus may not describe these tax consequences fully. </B></FONT><B>You should read the tax discussion
in the applicable Prospectus Supplement and consult with your own tax advisor with respect to your own particular circumstances.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The enforcement by investors of civil
liabilities under the United States federal securities laws may be affected adversely by the fact that the Corporation is incorporated
under the laws of Alberta, Canada, that the majority of its officers and directors are residents of Canada, that many of the experts
named in this Prospectus are not residents of the United States, and that a substantial portion of the assets of the Corporation
and said persons are located outside the United States. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THE SEC NOR ANY STATE OR CANADIAN
SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THE SECURITIES OFFERED HEREBY OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR
COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All shelf information permitted under applicable
securities legislation to be omitted from this Prospectus including, without limitation, the information disclosed in the specific
terms of any offering of Securities, as discussed above, will be contained in one or more Prospectus Supplements that will be delivered
to purchasers together with this Prospectus, except in cases where an exemption from such delivery requirements has been obtained.
Each Prospectus Supplement will be incorporated by reference into this Prospectus for the purposes of securities legislation as
of the date of such Prospectus Supplement and only for the purposes of the distribution of the Securities to which that Prospectus
Supplement pertains.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell the Securities to or through
one or more underwriters or dealers purchasing as principals and may also sell the Securities to one or more purchasers directly,
through applicable statutory exemptions, or through one or more agents designated by us from time to time. The Securities may be
sold from time to time in one or more transactions at fixed prices or not at fixed prices, such as market prices prevailing at
the time of sale, prices related to such prevailing market prices or prices to be negotiated with purchasers, which prices may
vary as between purchasers and during the period of distribution of the Securities. The Prospectus Supplement relating to a particular
offering of Securities will identify each underwriter, dealer or agent engaged in connection with the offering and sale of such
Securities, as well as the method of distribution and the terms of the offering of such Securities, including the initial offering
price (in the event the offering is a fixed price distribution), the manner of determining the offering price(s) (in the event
the offering is not a fixed price distribution), the net proceeds to us and, to the extent applicable, any fees, discounts or any
other compensation payable to underwriters, dealers or agents and any other material terms. See &ldquo;<I>Plan of Distribution</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with any offering of the
Securities other than an &ldquo;at-the-market distribution&rdquo; (as defined under applicable Canadian legislation) (unless otherwise
specified in the relevant Prospectus Supplement), the underwriters or agents may over-allot or effect transactions that stabilize
or maintain the market price of the offered Securities at a level above that which might otherwise prevail on the open market.
Such transactions, if commenced, may be interrupted or discontinued at any time. See &ldquo;<I>Plan of Distribution</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No underwriter or dealer involved in an
 &ldquo;at-the-market distribution&rdquo; under this Prospectus, no affiliate of such an underwriter or dealer and no person or
company acting jointly or in concert with such underwriter or dealer will over-allot securities in connection with such distribution
or effect any other transactions that are intended to stabilize or maintain the market price of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Owning the Securities may subject you to
tax consequences. This Prospectus and any applicable Prospectus Supplement may not describe the tax consequences fully. You should
read the tax discussion in any applicable Prospectus Supplement and consult with your own tax advisor with respect to your own
particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Unless otherwise specified in the applicable
Prospectus Supplement, the Subscription Receipts, Warrants and Units will not be listed on any securities exchange. There is no
market through which these securities may be sold and purchasers may not be able to resell such securities purchased under this
Prospectus. This may affect the pricing of such securities in the secondary market, the transparency and availability of trading
prices, the liquidity of such securities, and the extent of issuer regulation. See &ldquo;<I>Forward-Looking Statements</I>&rdquo;
and &ldquo;<I>Risk Factors</I>&rdquo;.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our outstanding Common Shares are listed
for trading on the Toronto Stock Exchange under the trading symbol &ldquo;ONC&rdquo; and on the Nasdaq Capital Market under the
trading symbol &ldquo;ONCY&rdquo;. On June 11, 2020, the closing price of our Common Shares on the Toronto Stock Exchange and
Nasdaq Capital Market was $2.80 and US$1.95 per Common Share, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Messrs. Wayne Pisano and Leonard Kruimer
and Drs. William G. Rice and Bernd R. Seizinger are directors of the Corporation who reside outside of Canada. Messrs. Pisano and
Kruimer and Drs. Rice and Seizinger have appointed the Corporation, at its principal place of business, as agent for service of
process. Purchasers are advised that it may not be possible for investors to enforce judgments obtained in Canada against any person
that resides outside of Canada, even if the party has appointed an agent for service of process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No underwriter, agent or dealer has
been involved in the preparation of this Prospectus or performed any review of the contents of this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7. Our registered office is located at
4000, 421&nbsp;-&nbsp;7<SUP>th</SUP>&nbsp;Avenue S.W., Calgary, Alberta, T2P&nbsp;4K9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>TABLE
OF CONTENTS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; width: 90%; text-align: right; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; width: 10%; text-align: center; font-weight: bold; text-indent: 0">Page</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: right; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; font-weight: bold; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_001">ABOUT THIS PROSPECTUS AND OTHER MATTERS</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_001">4</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_002">FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_002">4</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_003">RISK FACTORS</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_003">6</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_004">DOCUMENTS INCORPORATED BY REFERENCE</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_004">6</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_005">DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_005">8</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_006">ADDITIONAL INFORMATION</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_006">8</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_007">THE CORPORATION</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_007">8</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_008">BUSINESS OF THE CORPORATION</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_008">9</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_009">CONSOLIDATED CAPITALIZATION</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_009">11</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_010">USE OF PROCEEDS</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_010">11</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_011">DESCRIPTION OF SHARE CAPITAL</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_011">11</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_012">DESCRIPTION OF SUBSCRIPTION RECEIPTS</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_012">12</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_013">DESCRIPTION OF WARRANTS</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_013">13</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_014">DESCRIPTION OF UNITS</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_014">13</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_015">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_015">14</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_016">PRIOR SALES</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_016">15</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_017">TRADING PRICE AND VOLUME</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_017">15</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_018">CERTAIN INCOME TAX CONSIDERATIONS</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_018">15</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_019">LEGAL MATTERS AND INTEREST OF EXPERTS</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_019">15</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_020">AUDITORS, TRANSFER AGENT AND REGISTRAR</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_020">16</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_021">ENFORCEABILITY OF CIVIL LIABILITIES AGAINST NON-U.S. PERSONS</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_021">16</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-transform: uppercase; text-indent: 0"><A HREF="#a_022">AGENT FOR SERVICE OF PROCESS</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-transform: uppercase; text-indent: 0"><A HREF="#a_022">16</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_001"></A>ABOUT THIS PROSPECTUS
AND OTHER MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Prospectus and any Prospectus Supplement,
unless otherwise indicated, references to &ldquo;<B>we</B>&rdquo;, &ldquo;<B>us</B>&rdquo;, &ldquo;<B>our</B>&rdquo;, &ldquo;<B>issuer</B>&rdquo;,
 &ldquo;<B>Oncolytics</B>&rdquo; or the &ldquo;<B>Corporation</B>&rdquo; are to Oncolytics Biotech Inc., including, where the context
requires, its subsidiaries and affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In this Prospectus and in any Prospectus
Supplement, unless otherwise specified or the context otherwise requires, all references to &ldquo;<B>dollars</B>&rdquo;, &ldquo;<B>Cdn.$</B>&rdquo;
or &ldquo;<B>$</B>&rdquo; are to Canadian dollars and all references to &ldquo;<B>US$</B>&rdquo; are to United States dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, all financial
information included and incorporated by reference in this Prospectus and any Prospectus Supplement is determined using IFRS as
issued by IASB and adopted by the Accounting Standards Board of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Prospectus provides you with a general
description of the Securities that the Corporation may offer. Each time the Corporation sells Securities under this Prospectus,
the Corporation will file and deliver, except in cases where an exemption from such delivery requirement has been obtained, a Prospectus
Supplement that will contain specific information about the terms of that offering of Securities. The Prospectus Supplement also
may add, update or change information contained in this Prospectus. Before investing, investors should read both this Prospectus
and any applicable Prospectus Supplement together with additional information described under the heading &ldquo;<I>Documents Incorporated
by Reference</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should rely only on the information
contained in or incorporated by reference in this Prospectus or any applicable Prospectus Supplement. The Corporation has not authorized
anyone to provide you with different or additional information. The Corporation is not making an offer of these Securities in any
jurisdiction where the offer is not permitted by law. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_002"></A>FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Prospectus and the documents incorporated
by reference herein contain certain statements relating to future events or the Corporation&rsquo;s future performance which constitute
forward-looking statements within the meaning of applicable Canadian securities laws and within the meaning of the United States
Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or achievements of the Corporation, or industry results, to be
materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Forward-looking statements are statements that are not historical facts, and include, but are not limited to, estimates and their
underlying assumptions; statements regarding plans, objectives and expectations with respect to the efficacy of our technologies;
the timing and results of clinical studies related to our technologies; future operations, products and services; the impact of
regulatory initiatives on our operations; the size of and opportunities related to the markets for our technologies; general industry
and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future
performance. Forward-looking statements generally, but not always, are identified by the words &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
 &ldquo;believes,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects&rdquo;, &ldquo;potential&rdquo;, &ldquo;possible&rdquo;
and similar expressions, or that events or conditions &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;could&rdquo; or &ldquo;should&rdquo;
occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The forward-looking statements in this
Prospectus are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control,
including without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to all of our products, including pelareorep, being in the research and development
stage and requiring further development and testing before they can be marketed commercially;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks inherent in pharmaceutical research and development;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to timing and possible delays in our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to some of our clinical trials being conducted in, and subject to the laws of, foreign
countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our pharmaceutical products being subject to intense regulatory approval processes
in the United States and other foreign jurisdictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to being subject to government manufacturing and testing regulations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the extremely competitive biotechnology industry and our competition with larger
companies with greater resources;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our reliance on patents and proprietary rights to protect our technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to potential product liability claims;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our limited manufacturing experience and reliance on third parties to commercially
manufacture our products, if and when developed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our new products not being accepted by the medical community or consumers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our technologies becoming obsolete;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our dependence on third party relationships for research and clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our license, development, supply and distribution agreement with Adlai Nortye
Biopharma Co. Ltd.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our lack of operating revenues and history of losses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">uncertainty regarding our ability to obtain third-party reimbursement for the costs of our product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to other third-party arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our ability to obtain additional financing to fund future research and development
of our products and to meet ongoing capital requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to potential increases in the cost of director and officer liability insurance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our dependence on key employees and collaborators;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to Barbados law, including those relating to the enforcement of judgments obtained
in Canada or the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the effect of changes in the law on our corporate structure;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to expenses in foreign currencies and our exposure to foreign currency exchange rate
fluctuations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to data privacy laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our information technology systems and security breaches;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our compliance with the Sarbanes-Oxley Act of 2002, as amended;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our status as a foreign private issuer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to possible &ldquo;passive foreign investment company&rdquo; status;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to fluctuations in interest rates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to information technology systems;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to business interruptions resulting from pandemics and public health emergencies,
including those related to COVID-19 coronavirus, geopolitical actions, including war and terrorism or natural disasters including
earthquakes, typhoons, floods and fires; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our Securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This list is not exhaustive of the factors
that may affect any of the Corporation&rsquo;s forward-looking statements. Some of the important risks and uncertainties that could
affect forward-looking statements are described further under the heading &ldquo;<I>Risk Factors</I>&rdquo; in our Annual Report.
If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, our actual results may
vary materially from those expected, estimated or projected. Forward-looking statements in this document are not a prediction of
future events or circumstances, and those future events or circumstances may not occur. Given these uncertainties, users of the
information included herein, including investors and prospective investors, are cautioned not to place undue reliance on such forward-looking
statements. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to forward-looking statements. The Corporation does not undertake any obligation
to publicly update or revise any forward-looking statements other than as required under applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prospective investors should carefully
consider the information contained under the heading &ldquo;<I>Risk Factors</I>&rdquo; in our Annual Report and all other information
included in or incorporated by reference in this Prospectus before making investment decisions with regard to the Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_003"></A>RISK FACTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>An investment in the Securities involves
a high degree of risk. Prospective investors should note that there is no market through which the Subscription Receipts, Warrants
or Units may be sold and purchasers may not be able to resell the Subscription Receipts, Warrants or Units purchased under this
Prospectus. This may affect the pricing of these securities in the secondary market, the transparency and availability of trading
prices, the liquidity of the securities, and the extent of issuer regulation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prospective investors should consider carefully
the risks described in the documents incorporated by reference in this Prospectus (including in subsequently filed documents incorporated
by reference) and those described in any Prospectus Supplement before purchasing the Securities offered hereby. Discussions of
certain risks affecting the Corporation in connection with its business are provided under the heading &ldquo;<I>Risk Factors</I>&rdquo;
in our Annual Report filed with the various securities regulatory authorities, which is incorporated by reference in this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_004"></A>DOCUMENTS INCORPORATED
BY REFERENCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information has been incorporated by
reference in this Prospectus from documents filed with securities commissions or similar authorities in Canada. </B>Copies of the
documents incorporated herein by reference may be obtained on request without charge from our Corporate Secretary at 210, 1167
Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7 telephone (403)&nbsp;670-7377, and are available electronically under
the Corporation&rsquo;s profile on SEDAR (www.sedar.com) and on EDGAR (www.sec.gov/edgar.shtml).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed the following documents with
the securities commissions or similar regulatory authorities in certain of the provinces of Canada and such documents are specifically
incorporated by reference in, and form an integral part of, this Prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify">our <A HREF="http://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/oncyf2019-20f.htm" STYLE="-sec-extract: exhibit">annual report</A> on Form 20-F (&ldquo;<B>Annual Report</B>&rdquo;) dated March 6, 2020, for the
year ended December 31, 2019 (filed in Canada with certain Canadian securities regulatory authorities as our annual information
form for the year ended December 31, 2019);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify">our <A HREF="http://www.sec.gov/Archives/edgar/data/1129928/000110465920048027/tm2016145-1_ex991.htm" STYLE="-sec-extract: exhibit">management information circular</A> dated March 16, 2020 relating to the annual general meeting
of shareholders held on May 7, 2020;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify">our <A HREF="http://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/oncyf2019-20f.htm" STYLE="-sec-extract: exhibit">audited consolidated financial statements</A>, together with the notes thereto, as at December
31, 2019 and 2018, which comprise the consolidated statements of financial position as at December 31, 2019 and 2018, and the consolidated
statements of loss and comprehensive loss, changes in equity, and cash flows for the years ended December 31, 2019, 2018 and 2017,
together with the independent auditors&rsquo; report thereon; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify">our <A HREF="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex151-2019mda.htm" STYLE="-sec-extract: exhibit">management&rsquo;s discussion and analysis</A> of financial condition and results of operations
dated March 5, 2020, for the year ended December 31, 2019;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(e)</FONT></TD><TD STYLE="text-align: justify">our <A HREF="http://www.sec.gov/Archives/edgar/data/1129928/000112992820000024/ex991-interimfsmar312020.htm" STYLE="-sec-extract: exhibit">unaudited interim consolidated financial statements</A>, together with the notes thereto, as at
March 31, 2020, which comprise the interim consolidated statements of financial position as at March 31, 2020 and December 31,
2019, and the interim consolidated statements of income (loss) and comprehensive income (loss), changes in equity, and cash flows
for the three months ended March 31, 2020 and 2019; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(f)</FONT></TD><TD STYLE="text-align: justify">our <A HREF="http://www.sec.gov/Archives/edgar/data/1129928/000112992820000024/ex992-q12020mda.htm" STYLE="-sec-extract: exhibit">management&rsquo;s discussion and analysis</A> of financial condition and results of operations
dated May 7, 2020, for the three months ended March 31, 2020.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any documents of the type required by National
Instrument 44-101 - <I>Short Form Prospectus Distributions</I> to be incorporated by reference in a short form prospectus, including
any annual information form, annual report on Form 20-F, comparative annual consolidated financial statements and the auditors&rsquo;
report thereon, comparative interim consolidated financial statements, management&rsquo;s discussion and analysis of financial
condition and results of operations, material change report (except a confidential material change report), business acquisition
report and information circular, if filed by us with the securities commissions or similar authorities in Canada after the date
of this Prospectus and prior to the date which is 25 months from the date of this Prospectus, shall be deemed to be incorporated
by reference in this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, to the extent that any document
or information incorporated by reference into this Prospectus is included in any report filed with or furnished to the SEC pursuant
to the United States Securities Exchange Act of 1934, as amended (the &ldquo;<B>U.S. Exchange Act</B>&rdquo;), after the date of
this Prospectus, such document or information shall be deemed to be incorporated by reference as an exhibit to the registration
statement of which this Prospectus forms a part (in the case of documents or information deemed furnished on Form 6-K or Form 8-K,
only to the extent specifically stated therein)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Any statement contained in this Prospectus
or in a document incorporated or deemed to be incorporated by reference herein will be deemed to be modified or superseded for
the purposes of this Prospectus to the extent that a statement contained in this Prospectus or in any other subsequently filed
document which also is, or is deemed to be, incorporated by reference into this Prospectus modifies or supersedes that statement.
The modifying or superseding statement need not state that it has modified or superseded a prior statement or include any other
information set forth in the document that it modifies or supersedes. The making of a modifying or superseding statement shall
not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation,
an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary
to make a statement not misleading in light of the circumstances in which it was made. Any statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute part of this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon a new annual information form and
the related audited annual financial statements and management&rsquo;s discussion and analysis being filed by us with the applicable
securities regulatory authorities during the term of this Prospectus, the previous annual information form, the previous audited
annual financial statements and related management&rsquo;s discussion and analysis, all unaudited interim financial statements
and related management&rsquo;s discussion and analysis, material change reports and business acquisition reports filed prior to
the commencement of our financial year in which the new annual information form and the related audited annual financial statements
and management&rsquo;s discussion and analysis are filed shall be deemed no longer to be incorporated into this Prospectus for
purposes of future offers and sales of Securities hereunder. Upon new interim financial statements and related management&rsquo;s
discussion and analysis being filed by us with the applicable securities regulatory authorities during the term of this Prospectus,
all interim financial statements and related management&rsquo;s discussion and analysis filed prior to the new interim consolidated
financial statements and related management&rsquo;s discussion and analysis shall be deemed no longer to be incorporated into this
Prospectus for purposes of future offers and sales of Securities hereunder. Upon a new information circular relating to an annual
general meeting of holders of Common Shares being filed by us with the applicable securities regulatory authorities during the
term of this Prospectus, the information circular for the preceding annual general meeting of holders of Common Shares shall be
deemed no longer to be incorporated into this Prospectus for purposes of future offers and sales of Securities hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any &ldquo;template version&rdquo; of any
 &ldquo;marketing materials&rdquo; (as such terms are defined in National Instrument 41-101) pertaining to a distribution of Securities
will be filed under the Corporation&rsquo;s profile on SEDAR (www.sedar.com). In the event that such marketing materials are filed
subsequent to the date of filing of the applicable prospectus supplement pertaining to the distribution of the Securities to which
such marketing materials relates and prior to the termination of such distribution, such filed versions of the marketing materials
will be deemed to be incorporated by reference into the Prospectus for purposes of future offers and sales of Securities hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One or more Prospectus Supplements containing
the specific variable terms for an issue of the Securities and other information in relation to such Securities will be delivered
to purchasers of such Securities together with this Prospectus, except in cases where an exemption from such delivery requirement
has been obtained, and will be deemed to be incorporated by reference into this Prospectus as of the date of the Prospectus Supplement
solely for the purposes of the offering of the Securities covered by any such Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_005"></A>DOCUMENTS FILED AS
PART OF THE REGISTRATION STATEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documents have been or will
be filed with the SEC as part of the registration statement of which this Prospectus forms a part: (i)&nbsp;the documents set out
under the heading &ldquo;<I>Documents Incorporated by Reference</I>&rdquo;; (ii)&nbsp;the consent of the Corporation&rsquo;s auditor;
and (iii)&nbsp;the powers of attorney from the directors and certain officers of the Corporation. A copy of the form of warrant
indenture, unit indenture or subscription receipt agreement, as applicable, will be filed by post-effective amendment or by incorporation
by reference to documents filed or furnished with the SEC under the U.S.&nbsp;Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_006"></A>ADDITIONAL INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has filed with the SEC
a registration statement on Form F-10 relating to the Securities. This Prospectus, which constitutes a part of the registration
statement, does not contain all of the information contained in the registration statement, certain items of which are contained
in the exhibits to the registration statement as permitted by the rules and regulations of the SEC. See &ldquo;<I>Documents Filed
as Part of the Registration Statement</I>&rdquo;. Statements included or incorporated by reference in this Prospectus about the
contents of any contract, agreement or other documents referred to are not necessarily complete, and in each instance you should
refer to the exhibits to the registration statement for a more complete description of the matter involved. The registration statement,
and the items of information omitted from this Prospectus but contained in the registration statement, will be available on EDGAR
(www.sec.gov/edgar.shtml). Each time we sell Securities under the registration statement, we will provide a Prospectus Supplement
that will contain specific information about the terms of that offering. The Prospectus Supplement may also add to, update or change
information contained in this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation is subject to the information
requirements of the U.S.&nbsp;Exchange Act and applicable Canadian securities legislation and, in accordance therewith, files and
furnishes annual and quarterly financial information and material change reports, business acquisition reports and other material
with the securities commission or similar regulatory authority in each of the provinces of Canada and with the SEC. Under MJDS
adopted by the United States and Canada, documents and other information that the Corporation files with the SEC may be prepared
in accordance with the disclosure requirements of Canada, which are different from those of the United States. As a foreign private
issuer within the meaning of rules made under the U.S.&nbsp;Exchange Act, the Corporation is exempt from the rules under the U.S.&nbsp;Exchange
Act prescribing the furnishing and content of proxy statements, and the Corporation&rsquo;s officers, directors and principal shareholders
are exempt from the reporting and shortswing profit recovery provisions contained in Section&nbsp;16 of the U.S.&nbsp;Exchange
Act. In addition, the Corporation is not required to publish financial statements as promptly as United States companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Corporation&rsquo;s
reports and other information filed or furnished with or to the SEC are available from the SEC&rsquo;s Electronic Document Gathering
and Retrieval System, or EDGAR, at www.sec.gov, as well as from commercial document retrieval services. The Corporation&rsquo;s
Canadian filings are available on the System for Electronic Document Analysis and Retrieval, or SEDAR, at www.sedar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_007"></A>THE CORPORATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Biotech Inc. was incorporated
pursuant to the ABCA on April 2, 1998 as 779738 Alberta Ltd. On April 8, 1998, we amended our articles of incorporation (the &ldquo;<B>Articles</B>&rdquo;)
and changed our name to Oncolytics Biotech Inc. On July 29, 1999, we amended our Articles by removing the private company restrictions
included therein and subdivided the 2,222,222 Common Shares issued and outstanding into 6,750,000 Common Shares. On February 9,
2007, we amended our Articles to permit shareholder meetings to be held at any place in Alberta or at any other location as determined
by our board of directors. On May 22, 2018, we amended our Articles of Incorporation to effect a consolidation of the Common Shares
on the basis of 9.5 pre-consolidation Common Shares for each one post-consolidation Common Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have two material operating subsidiaries:
Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (US) Inc., a Delaware corporation. Oncolytics Biotech (Barbados) Inc.
is incorporated pursuant to the laws of Barbados and is a wholly-owned direct subsidiary of the Corporation. Oncolytics Biotech
(U.S.) Inc. is incorporated pursuant to the laws of Delaware and is a wholly-owned direct subsidiary or Oncolytics Biotech (Barbados)
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N 1X7. Our registered office is located at 4000,
421 - 7th Avenue S.W., Calgary, Alberta, T2P 4K9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_008"></A>BUSINESS OF THE CORPORATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">General</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since our inception in April of 1998, Oncolytics
Biotech Inc. has been a development stage company and we have focused our research and development efforts related to pelareorep,
a systemically administered immuno-oncology (&ldquo;<B>I-O</B>&rdquo;) viral agent with the potential to treat a variety of cancers.
We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and
development efforts. We do not expect to generate significant revenues until, if and when, pelareorep becomes commercially viable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our potential product for human use, pelareorep,
an unmodified reovirus, is a first in class systemically administered I-O viral agent for the treatment of solid tumors and hematological
malignancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further information regarding the business
of the Corporation is contained in the Annual Report under the heading &ldquo;<I>Item 4 &ndash; Information on the Company</I>&rdquo;,
which document is incorporated by reference in this Prospectus. See &ldquo;<I>Documents Incorporated by Reference</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Recent Developments</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">On
May 14, 2020 we announced the publication of two <FONT STYLE="font-size: 10pt; color: #444444; background-color: white">abstracts&nbsp;in
</FONT>connection with the upcoming ASCO Virtual Annual Meeting on May 29-31. The first abstract&nbsp;(&quot;</FONT>Multiple Myeloma
Abstract<FONT STYLE="font-weight: normal">&quot;), which has been accepted as an electronic poster, reports&nbsp;on viral replication,
tumor immune responses,&nbsp;and treatment safety in multiple myeloma patients treated with&nbsp;pelareorep&nbsp;in combination
with&nbsp;carfilzomib&nbsp;(Kyprolis&reg;).&nbsp;The second abstract (&quot;</FONT>Pancreatic Cancer Abstract<FONT STYLE="font-weight: normal">&quot;)
reports&nbsp;on treatment&nbsp;tolerability&nbsp;and&nbsp;efficacy in pancreatic cancer patients treated with&nbsp;pelareorep,&nbsp;in
combination with pembrolizumab&nbsp;(Keytruda&reg;).&nbsp;&nbsp; </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">The
Multiple Myeloma Abstract highlighted the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Reported selective infection of cancerous cells with pelareorep,
with associated CD8+ and natural killer (NK) cell recruitment, PD-L1 upregulation, activated caspase-3 expression, and increased
pelareorep protein production within myeloma cells.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Two patients achieved unconfirmed partial responses, two patients
had stable disease, and two patients had progressive disease. All patients had advanced and challenging to treat carfilzomib-refractory
disease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Of the two responding patients, one patient developed a fever
and grade 4 thrombocytopenia that resolved, and the other patient developed a cytokine storm, associated with rapid tumor lysis.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Data supports the potential of future studies investigating pelareorep,
carfilzomib, and immune checkpoint inhibitor combination therapy in multiple myeloma patients.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Additional data to be presented at the poster session on May
29, 2020.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">The
Pancreatic Cancer Abstract highlighted the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Preliminary data indicate that the combination of pelareorep
and pembrolizumab resulted in tumor-specific replication, a high degree of T cell repertoire turnover, and the creation of new
T cell clones in the peripheral blood during treatment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The treatment was found to be well tolerated, with most treatment-related
adverse events being grade 1 or 2.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">One patient achieved a partial response and three achieved stable
disease, with an overall disease control rate of 30% in evaluable patients.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The study will not proceed to stage 2 in unselected patients,
however further evaluation of the anti-tumor activity of pelareorep and anti-PD-1 therapy is now planned in biomarker defined pancreatic
patients in a subsequent study.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Detailed translational and biomarker data from this study will
be published later in the year.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2020, we announced the publication
of an electronic-poster (&ldquo;<B>ePoster</B>&rdquo;) with clinical data from the Corporation's AWARE-1 window-of-opportunity
breast cancer study. The data demonstrates a pelareorep-induced adaptive immune response in the tumor microenvironment (&ldquo;<B>TME</B>&rdquo;)
and the potential of a predictive biomarker (T cell clonality) to identify patients with breast cancer most likely to respond to
pelareorep.&nbsp;The ePoster was published on May 23, 2020 and presented as part of the European Society for Medical Oncology Breast
Cancer Virtual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Key data and conclusions
from this ePoster include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Intravenous systemic administration resulted in tumor cell-specific pelareorep replication.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">All patients treated with pelareorep demonstrated an increase in CD8+ T cells as confirmed in tumor
biopsies (range of 1.6-fold to 11.2-fold increase).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">All patients treated with pelareorep experienced an increase in the number of PD-L1 positive cells
in their tumors in as early as three weeks after beginning treatment (range of 1.3-fold to 11.0-fold increase).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Four out of six evaluated patients exhibited an increase in tumor cellularity and tumor-infiltrating
lymphocytes (&ldquo;<B>CelTIL</B>&rdquo;), which is associated with favorable clinical response, the study's primary endpoint.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Peripheral T cell clonality correlated with changes in the TME and CelTIL, highlighting its potential
as a compelling biomarker of pelareorep response in breast cancer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results show intravenous delivery of
pelareorep reaches the primary breast cancer tumor target.&nbsp; Importantly, the large increase in CD8+ T cells is prognostic
of positive treatment outcomes, and the increased expression of PD-L1 suggests a treatment synergy when combining pelareorep and
anti-PD-L1 checkpoint inhibitors, such as Tecentriq&reg;. The correlation between T cell clonality and tumor inflammation continues
to show promise across multiple indications and increases our ability to identify patients likely to respond to treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 29, 2020, we announced the publication
of an ePoster with clinical proof-of-concept data from the Corporation's phase 1b study in carfilzomib-refractory multiple myeloma
patients treated with pelareorep in combination with carfilzomib (Kyprolis&reg;). Data presented in this ePoster demonstrates that
the pelareorep-carfilzomib combination treatment results in selective replication of pelareorep in cancer cells and beneficial
induction of an inflamed tumor environment associated with clinical responses. The ePoster was published and presented as part
of the American Society of Clinical Oncology Virtual Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The ePoster,&nbsp;<I>Oncolytic
virus Pelareorep [P] plus Carfilzomib &amp; Dexamethasone [Kd] phase 1 trial in Carfilzomib-refractory patients (NCI9603): responses
with cytokine storm</I>&nbsp;was co-authored by Dr. Douglas W. Sborov MD, MS, Assistant Professor, Division of Hematology and Hematologic
Malignancies, University of Utah &ndash; Huntsman Cancer Institute, and Craig Hofmeister, M.D., MPH, Associate Professor, Department
of Hematology and Medical Oncology Emory University School of Medicine, as well as several other colleagues at institutions across
the United States. Key data and conclusions from six patients in the study are presented in this ePoster and include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Pelareorep targets and selectively replicates in multiple myeloma tumor cells.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Pelareorep, when combined with carfilzomib, activates a profound inflammatory response accompanied
by a 50% overall response rate and 83% clinical benefit rate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Three partial responses, one minimal response, one stable disease, and one progressive disease were
achieved among patients with advanced and difficult-to-treat carfilzomib-refractory disease.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Significant and rapid T cell activation led to a single incidence of cytokine storm associated with
tumor response after treatment with pelareorep and carfilzomib.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_009"></A>CONSOLIDATED CAPITALIZATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since March 31, 2020, the Corporation has
issued:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify">an aggregate of 2,449,658 Common Shares pursuant to an equity distribution agreement dated October
24, 2018 with Canaccord Genuity LLC at prices ranging from US$1.34 to US$2.34 per Common Share, with the weighted average price
being US$1.73 per Common Share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify">an aggregate of 213,181 Common Shares upon the exercise of Common Share purchase warrants at a
price of US$0.90 per Common Share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">an
                                         aggregate of 7,324 Common Shares upon the exercise of outstanding stock options granted
                                         pursuant to its amended and restated stock option plan at a price of $2.41 per Common
                                         Share; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">an
                                         aggregate of 4,734 Common Shares upon the vesting of restricted share awards granted
                                         pursuant to its amended and restated incentive share award plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as set forth above, there has been
no material change in the share and loan capital of the Corporation on a consolidated basis since March 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_010"></A>USE OF PROCEEDS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The use of proceeds from the issue and
sale of specific Securities pursuant to this Prospectus will be described in the Prospectus Supplement relating to the issuance
and sale of such Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_011"></A>DESCRIPTION OF SHARE
CAPITAL</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Authorized Capital</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital consists of an unlimited
number of Common Shares. The following is a summary of the provisions attached to our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Common Shares</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of our Common Shares are entitled
to one vote per share at meetings of shareholders, to receive such dividends as declared by the Board and to receive our remaining
property and assets upon dissolution or wind up. Our Common Shares are not subject to any future call or assessment and there are
no pre-emptive, conversion or redemption rights attached to such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at the date hereof, we have 40,492,010
Common Shares issued and outstanding. After giving effect to the exercise of all outstanding options to acquire Common Shares
and all outstanding share awards granted under the Corporation&rsquo;s Incentive Share Award Plan, we would have 42,938,570 Common
Shares issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Common Share Purchase
Warrants</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date hereof, we have 16,443,500
Common Share purchase warrants (the &ldquo;<B>2017 Warrants</B>&rdquo;) issued and outstanding. Each 9.5 2017 Warrants entitles
the holder to purchase one Common Share until June 1, 2022, at an exercise price of $9.025. The 2017 Warrants are subject to acceleration
if the volume weighted average price of the Common Shares equals or exceeds $2.50 for a period of 15 consecutive trading dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date hereof, we have 265,757
Common Share purchase warrants (the &ldquo;<B>2019 Warrants</B>&rdquo;) issued and outstanding. Each 2019 Warrant entitles the
holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, as of the date hereof, the
Corporation has outstanding a Common Share purchase warrant (the &ldquo;<B>Adlai Warrant</B>&rdquo;) exercisable by the holder
thereof until November 14, 2020 to purchase such number of Common Shares as is calculated by dividing US$6,000,000 by the Exercise
Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the Adlai Warrant, the
term &ldquo;<B>Exercise Price</B>&rdquo; means an amount equal to 120% of the volume weighted average trading price of the Common
Shares on the Nasdaq Capital Market (or, if the Common Shares are not then listed on the Nasdaq Capital Market, on the Toronto
Stock Exchange) for the five trading days immediately preceding the exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Adlai Warrant is subject to a right
to call by the Corporation upon the date of the enrollment of the fiftieth (50<SUP>th</SUP>) patient in a Phase 3 Study related
to pelareorep.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_012"></A>DESCRIPTION OF SUBSCRIPTION
RECEIPTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of the terms
of Subscription Receipts sets forth certain general terms and provisions of Subscription Receipts in respect of which a Prospectus
Supplement may be filed. The particular terms and provisions of Subscription Receipts offered by any Prospectus Supplement, and
the extent to which the general terms and provisions described below may apply thereto, will be described in the Prospectus Supplement
filed in respect of such Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subscription Receipts may be offered separately
or in combination with one or more other Securities. The Subscription Receipts will be issued under a subscription receipt agreement
(the&nbsp;&rdquo;<B>Subscription Receipt Agreement</B>&rdquo;). A copy of the Subscription Receipt Agreement will be filed by us
with the applicable securities regulatory authorities after it has been entered into by us and will be available electronically
under the Corporation&rsquo;s profile on SEDAR (www.sedar.com) and, if applicable, we will file with the SEC via EDGAR (www.sec.gov/edgar.shtml)
as exhibits to the registration statement of which this Prospectus is a part, or will incorporate by reference from a Report of
Foreign Private Issuer on Form 6-K that we file with the SEC, any Subscription Agreement describing the terms and conditions of
such Subscription Receipts that we are offering before the issuance of such Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Subscription Receipt Agreement,
original purchasers of Subscription Receipts will have a contractual right of rescission against the Corporation, following the
issuance of the underlying Common Share or other securities to such purchasers upon the surrender or deemed surrender of the Subscription
Receipts, to receive the amount paid for the Subscription Receipts in the event that this Prospectus or a Prospectus Supplement,
and any amendment thereto, contains a misrepresentation or is not delivered to such purchaser, provided such remedy for rescission
is exercised within 180&nbsp;days from the closing date of the offering of Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The description of general terms and provisions
of Subscription Receipts described in any Prospectus Supplement will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the number of Subscription Receipts offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the price at which the Subscription Receipts will be offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if other than Canadian dollars, the currency or currency unit in which the Subscription Receipts
are denominated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the procedures for the exchange of the Subscription Receipts into Common Shares or other securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the number of Common Shares or other securities that may be obtained upon exercise of each Subscription
Receipt;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and terms of any other Securities with which the Subscription Receipts will be
offered, if any, and the number of Subscription Receipts that will be offered with each Security;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the terms applicable to the gross proceeds from the sale of the Subscription Receipts plus any
interest earned thereon;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the material Canadian tax consequences of owning such Subscription Receipts; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any other material terms, conditions and rights (or limitations on such rights) of the Subscription
Receipts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Subscription Receipts that are not within the options and parameters set forth in this
Prospectus. In addition, to the extent that any particular terms of the Subscription Receipts described in a Prospectus Supplement
differ from any of the terms described in this Prospectus, the description of such terms set forth in this Prospectus shall be
deemed to have been superseded by the description of such differing terms set forth in such Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_013"></A>DESCRIPTION OF WARRANTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of the terms
of Warrants sets forth certain general terms and provisions of Warrants in respect of which a Prospectus Supplement may be filed.
The particular terms and provisions of Warrants offered by any Prospectus Supplement, and the extent to which the general terms
and provisions described below may apply thereto, will be described in the Prospectus Supplement filed in respect of such Warrants.
Warrants may be offered separately or in combination with one or more other Securities. If applicable, we will file with the SEC
as exhibits to the registration statement of which this Prospectus is a part, or will incorporate by reference from a current report
on Form 6-K that we file with the SEC, any warrant indenture or form of warrant describing the terms and conditions of such Warrants
that we are offering before the issuance of such Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The description of general terms and provisions
of Warrants described in any Prospectus Supplement will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and aggregate number of Warrants offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the price at which the Warrants will be offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if other than Canadian dollars, the currency or currency unit in which the Warrants are denominated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and terms of the Common Shares that may be acquired upon exercise of the Warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the date on which the right to exercise the Warrants will commence and the date on which the right
will expire;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the number of Common Shares that may be purchased upon exercise of each Warrant and the price at
which and currency or currencies in which that amount of securities may be purchased upon exercise of each Warrant;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and terms of any Securities with which the Warrants will be offered, if any, and
the number of the Warrants that will be offered with each Security;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the date or dates, if any, on or after which the Warrants and the related Securities will be transferable
separately;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the minimum or maximum amount, if any, of Warrants that may be exercised at any one time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether the Warrants will be subject to redemption or call, and, if so, the terms of such redemption
or call provisions; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any other material terms, conditions and rights (or limitations on such rights) of the Warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Warrants that are not within the options and parameters set forth in this Prospectus.
In addition, to the extent that any particular terms of the Warrants described in a Prospectus Supplement differ from any of the
terms described in this Prospectus, the description of such terms set forth in this Prospectus shall be deemed to have been superseded
by the description of such differing terms set forth in such Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_014"></A>DESCRIPTION OF UNITS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue Units comprised of one or
more of the other Securities described in this Prospectus in any combination. Each Unit will be issued so that the holder of the
Unit is also the holder of each Security included in the Unit. Thus, the holder of a Unit will have the rights and obligations
of a holder of each included Security. The unit agreement, if any, under which a Unit is issued may provide that the Securities
comprising the Unit may not be held or transferred separately, at any time or at any time before a specified date. If applicable,
we will file with the SEC as exhibits to the registration statement of which this Prospectus is a part, or will incorporate by
reference from a current report on Form 6-K that we file with the SEC, any unit agreement describing the terms and conditions of
such Units that we are offering before the issuance of such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The particular terms and provisions of
Units offered by any Prospectus Supplement, and the extent to which the general terms and provisions described below may apply
to them, will be described in the Prospectus Supplement filed in respect of such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The particular terms of each issue of Units
will be described in the related Prospectus Supplement. This description will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and aggregate number of Units offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the price at which the Units will be offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if other than Canadian dollars, the currency or currency unit in which the Units are denominated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the terms of the Units and of the Securities comprising the Units, including whether and under
what circumstances those securities may be held or transferred separately;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any provisions for the issuance, payment, settlement, transfer or exchange of the Units or of the
Securities comprising the Units; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any other material terms, conditions and rights (or limitations on such rights) of the Units.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Units that are not within the options and parameters set forth in this Prospectus.
In addition, to the extent that any particular terms of the Units described in a Prospectus Supplement differ from any of the terms
described in this Prospectus, the description of such terms set forth in this Prospectus shall be deemed to have been superseded
by the description of such differing terms set forth in such Prospectus Supplement with respect to such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_015"></A>PLAN OF DISTRIBUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell the Securities to or through
one or more underwriters or dealers purchasing as principals and we may also sell the Securities to one or more purchasers directly,
through applicable statutory exemptions, or through one or more agents designated from time to time. The Securities may be sold
from time to time in one or more transactions at fixed prices or not at fixed prices, such as market prices prevailing at the time
of sale, prices related to such prevailing market prices or prices to be negotiated with purchasers, which prices may vary as between
purchasers and during the period of distribution of the Securities. The Prospectus Supplement relating to a particular offering
and sale of Securities will identify each underwriter, dealer or agent engaged in connection with the offering and sale of such
Securities, as well as the method of distribution and the terms of the offering and sale of such Securities, including the initial
offering price (in the event the offering is a fixed price distribution), the manner of determining the offering price(s) (in the
event the offering is not a fixed price distribution), the net proceeds to us and, to the extent applicable, any fees, discounts
or any other compensation payable to underwriters, dealers or agents and any other material terms. Only underwriters so named in
the Prospectus Supplement are deemed to be underwriters in connection with the Securities offered and sold thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the underwriters purchase Securities
from us as principal, the Securities will be acquired by the underwriters for their own account and may be resold from time to
time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined
at the time of sale, at market prices prevailing at the time of sale or at prices related to such prevailing market prices. The
obligations of the underwriters to purchase such Securities as principal will be subject to certain conditions precedent, and the
underwriters will be obligated to purchase all the Securities offered and sold by the Prospectus Supplement if any of such Securities
are purchased. Any public offering price and any discounts or concessions allowed or re-allowed or paid to underwriters, dealers
or agents may be changed from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Securities may be sold from time
to time in one or more transactions at a fixed price or prices which may be changed or at market prices prevailing at the time
of sale, at prices related to such prevailing market prices or at negotiated prices. The prices at which the Securities may be
offered may vary as between purchasers and during the period of distribution. If, in connection with the offering of Securities
at a fixed price or prices, the underwriters have made a <I>bona fide</I> effort to sell all of the Securities at the initial
offering price fixed in the applicable Prospectus Supplement, the public offering price may be decreased and thereafter further
changed, from time to time, to an amount not greater than the initial public offering price fixed in such Prospectus Supplement,
in which case the compensation realized by the underwriters will be decreased by the amount that the aggregate price paid by purchasers
for the Securities is less than the gross proceeds paid to us by the underwriters. Any such reduction to the public offering price
will not affect the net proceeds received by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Securities may also be sold directly
by us, pursuant to applicable statutory exemptions, at such prices and upon such terms as agreed to by us and the purchaser or
through one or more agents designated by us from time to time. Any agent involved in the offering and sale of the Securities in
respect of which this Prospectus is delivered will be named, and any commissions payable by us to such agent will be set forth,
in the Prospectus Supplement. Unless otherwise indicated in the Prospectus Supplement, any agent would be acting on a best efforts
basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may agree to pay the underwriters a
commission for various services relating to the issue and sale of any Securities offered hereby. Any such commission will be paid
out of our general funds. Underwriters, dealers and agents who participate in the distribution of the Securities may be entitled
under agreements to be entered into with us to indemnification by us against certain liabilities under securities legislation,
or to contribution with respect to payments which such underwriters, dealers or agents may be required to make in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any offering of Subscription Receipts,
Warrants or Units will be a new issue of securities with no established trading market. Unless otherwise specified in the applicable
Prospectus Supplement, the Subscription Receipts, Warrants or Units will not be listed on any securities exchange. Certain dealers
may make a market in these Securities, but will not be obligated to do so and may discontinue any market making at any time without
notice. No assurance can be given that any dealer will make a market in these Securities or as to the liquidity of the trading
market, if any, for these Securities. See &ldquo;<I>Risk Factors</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise specified in a Prospectus
Supplement, in connection with any offering of the Securities, the underwriters or agents may over-allot or effect transactions
which stabilize or maintain the market price of the Securities offered at a higher level than that which might exist in the open
market. Such transactions, if commenced, may be interrupted or discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_016"></A>PRIOR SALES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information regarding prior sales of Securities
will be provided as required in a Prospectus Supplement with respect to the issuance of Securities pursuant to such Prospectus
Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_017"></A>TRADING PRICE AND
VOLUME</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information regarding trading price and
volume of the Securities will be provided as required for all of the Corporation&rsquo;s issued and outstanding Securities that
are listed on any securities exchange, as applicable, in each Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_018"></A>CERTAIN INCOME TAX
CONSIDERATIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The applicable Prospectus Supplement may
describe certain Canadian federal income tax consequences which may be applicable to a purchaser of Securities offered thereunder,
and may also include a discussion of certain United States federal income tax consequences to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_019"></A>LEGAL MATTERS AND
INTEREST OF EXPERTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise specified in the Prospectus
Supplement relating to an offering and sale of Securities, certain legal matters relating to such offering and sale of Securities
will be passed upon on behalf of the Corporation by McCarthy T&eacute;trault LLP with respect to matters of Canadian law and Dorsey
 &amp; Whitney LLP, with respect to matters of U.S. law. In addition, certain legal matters in connection with an offering and sale
of Securities will be passed upon for any underwriters, dealers or agents by counsel to be designated at the time of such offering
and sale by such underwriters, dealers or agents with respect to matters of Canadian and, if applicable, United States or other
foreign law. As at the date hereof, the partners and associates of McCarthy T&eacute;trault LLP, as a group, own less than 1% of
the outstanding securities of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_020"></A>AUDITORS, TRANSFER
AGENT AND REGISTRAR</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The auditors of the Corporation are Ernst
 &amp; Young LLP, Chartered Accountants, Calgary City Centre, 2200, 215 &ndash; 2<SUP>nd</SUP> Street S.W., Calgary, Alberta, T2P
1M4. Ernst &amp; Young LLP is independent of the Corporation in accordance with the Rules of Professional Conduct as outlined by
the Chartered Professional Accountants of Alberta. Ernst &amp; Young LLP is registered with the U.S. Public Corporation Accounting
Oversight Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for the
Common Shares is AST Trust Company (Canada) at its principal offices located in Montreal, Quebec.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_021"></A>ENFORCEABILITY OF
CIVIL LIABILITIES AGAINST NON-U.S. PERSONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation is a corporation existing
under the <I>Business Corporations Act</I> (Alberta). Most of the Corporation&rsquo;s directors and officers, and some or all of
the experts named in this Prospectus, are residents of Canada or otherwise reside outside the United States, and all or a substantial
portion of their assets, and substantially all of the Corporation&rsquo;s assets, are located outside the United States. The Corporation
has appointed an agent for service of process in the United States, but it may be difficult for holders of Securities who reside
in the United States to effect service within the United States upon those directors, officers and experts who are not residents
of the United States. It may also be difficult for holders of Securities who reside in the United States to realize in the United
States upon judgments of courts of the United States predicated upon the Corporation&rsquo;s civil liability and the civil liability
of its directors, officers and experts under the United States federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation filed with the SEC, concurrently
with its registration statement on Form&nbsp;F-10 of which this Prospectus is a part, an appointment of agent for service of process
on Form&nbsp;F-X. Under the Form&nbsp;F-X, the Corporation appointed DL&nbsp;Services Inc. as its agent for service of process
in the United States in connection with any investigation or administrative proceeding conducted by the SEC, and any civil suit
or action brought against or involving the Corporation in a United States court arising out of or related to or concerning the
offering of the Securities under this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_022"></A>AGENT FOR SERVICE
OF PROCESS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Messrs. Wayne Pisano and Leonard Kruimer
and Drs. William G. Rice and Bernd R. Seizinger are directors are directors of the Corporation who reside outside of Canada. Messrs.
Pisano and Kruimer and Drs. Rice and Seizinger have appointed the Corporation, at its principal place of business, as agent for
service of process. Purchasers are advised that it may not be possible for investors to enforce judgments obtained in Canada against
any person that resides outside of Canada, even if the party has appointed an agent for service of process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 45; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
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M.<9!^AZ53\0?$#1?#E^+"Y>XN+W;N-O:Q&1U'J>PJ?PWXUTGQ5)/%ISS+<0
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M_*NI\8V-]'K6A:_8V4FH+ICRB:TCQO*R*%W(#U(QTK9T+7&UR.:0Z9J-@D9
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8HHHHHHHHHHHHHHHHHHHHHHHHHHHHK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" %F ;\# 2(  A$! Q$!_\0
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M@XHSFDZTT9S0!)BDQ12XH 80:4&G=JB!^:@"3;01D4HY%(: & 8-.!HXH H
M&&1354@U)BB@!: ,TF:86(H >ZTF,"@-FG"@!HIIY:GG I.,T /[4FVBC- "
M$4BCFE8X%(AR: ',@K4\,\>(;3ZO_P"@-66QK3\,#_BH;3ZO_P"@-0*6QE@8
MI"<&D<D4T'- R3.:* *<%H 2B@THH 8QYHQ2D<TQVP<4 /6FOR:56R*-W-
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MP<TNV@!0PIKC-!!I,F@!RCC%+C%(.E&^@!::QYIP.:C8?-0 I7-.'2A0<44
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M/KS4T?A&VD^P[)KA4F(#R2 +D["VT*1G/&!U%,=XB_\ "80F^$TD=PRK>&=
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MY*C /3CCBJ!(%(#S0%D7SJUZ1C[0V/+:'H/N,<L/Q--NM3O+V%(KF<R(F,9
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M>],9!%<S6ZL()60-U"GK3=S/MW,3M 49[#TJ66T:$1$Y8N@? '3DC'Z5"W%
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M>.S"J%Z&N$-S$&(/WD7KGUQ3E&2?+(3:Z&U/K+$ H-JFLRZOVE@>2)\2Q\D
M\$5GQ"\FB(:"4AO[PJYIED\4<SW/R*B$G=]*<HQ3]T2=S-:_#MG=UYX/2I+6
M<3RM$#\LGRD5K+X8L_*#0Q*=P^\S'-1QZ=!:2J6AVE3G*FB57FW#E:92T_PW
M<_?N+[8C#(11S6C;>'(X[A9))Y&0')#+C/TI%U9[=RDP ;L.WM4[:@+B(.C$
M\<CTH2G/Y%>Z3@VD%U(5V+=2MEY73YL=@/0 59%ZJCYG9E]<<5B+,+P.@Y=<
MF-N^?2LR#5I7D:-5<J>VTFE%1;?.'-V.DEU-MY6-AD [<]Z@\/:JD_B2"-F/
MF$MQ_P  :LFR%Q<W\8:-U4MPQ&!BNC\.:'8KKB7ZKOE=W.2_"Y!' IP?(R7=
MILH0^&]04M)+-'U^51R<>]:6F:<5F*W!4+Z@=_I2-JKS+O1<JO%7;5)G E;G
M=V["HDIQ2<NIHDF9;ZLJ221[L/DJH/\ #44%TQ<J3E\G%:DGAJSFFDN9$8LS
M9.#@9J/['96DZF.,[O4G-.G44'[NX6=PA9+26./*FZ9-RHPYQZT3ZI"MQY&#
M/=8SLR5 ]LXY-5O$!DW&5RH0@1YXX)^Z<GICK^%<I!)+I]]AI(+U+@L!()OF
MZ=1@Y'/:NW#8>$USL\O&XJI2?)%FM'KM_-=M);;"LA4.F!P0/\*WDNH=5$:7
M"F!V/&.,^F:XB*[#7RJC,<*6<*NQ0 ?T.>/_ -=:FEWYOIC8N(X-C,4!)Y(/
M')YS_#]*[I4:<EM8\N&(JPE>]SHWM[6TGCCEE;?(Q5$9^6(["JVO3 :7"R<0
M"7$F5W <<9'?FF&*46T5RX<S$[7D<<D]B/3CL/ZU=AA2>S>*=6,,BX*],^]<
M47[&HDW>QZ<X^VI.45OM_P $XU;24%(G=57>3A.A[X').*Z'1=*>QD$MQ,#(
M\RM$%/Z^H]*@U+0KAHX/):/*'F??L(';.?R_&MRX:*90PVR7<: 93(P1WSZU
MVU:T(QO<\RCAZDI6L2S7"M+)@+M!.#FLJ>VM+Z52ZR)B02,R'&2/Y&H(YW<A
M<D.G\3  D_RK5TRTDO)1<RILA'#?[6*\R-94H^X]3WI8>-;^(.U2U,\Q\F11
MO4, 5(R#SG/K52/2@<//+'&J]=IS6R\Z7$AZ+&HPH^E9=RZDD87'3 %<TJCE
MJS=4HP5EH95[?1PQE[<,JOE4YR2HZL?3-5K#S;DN_G"(H,KN'7WJM?0E+@QJ
M,H>>35K3UN9Y5MA%'(IQ@L.@J8<M_?.]RDJ:C3=CH=.UZ%[B*TOVBNQ(" 2
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M:[F?1OLSIJ-C':JZ)Y-O$X"H!UW-_>P2WUR*Y_2=#"7PDU*V6ZCF.T3VSAQ
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M+N[U1B1;-'Y:-&"=I(^8L#QD$?G3HRG]IXC:4 88@DYSU_*K%O\ :)9;U9Y
M^GSL$A0$EXR,@M@_Y-/I9H&Y*7-^!A:F8KD1?9Y_](( 8O\ =?\ V@>V:P;J
M"2S>0R91P>5-;>HZ;=:),'RDL><@ =CW4^E9R7]M/+LN8T50>DJ\#\JCE.I5
ME+032M'EU=?.5D**X5UW $#UKI;^'3H=GF[;AXQ\J%L[5QCG'6JVGZ0=4+I:
MM%#;C^%'^4CU/MGUJ1M8\/\ AZ\,1B2^=/O2))D;O8=/UHL[63T+ER1:EU1;
MN+ ?8[G<KJA>*0 #.%VGG\JYIQ/<:B([6;Y4YWE3PO\ .NSM;^T\0Z6YA/V<
MM(-@8_+D@_*?05@W#-87#V5R;+&,,HD*G'O01%MR;D316<5[9F.^DQ#"-P=@
M5?)]14-LVGZ2LLBW680"H8]R>O'<5F2WGV>![:TF>2-NJ,V\#V!]*CN+&6;3
M7N)B6?S1U[ T<O,[L/:1I)J/4OP7.GR*2UO%,F<DH,,#6KI-G]IOVF:3?;%=
MS._'ECLH_P!HURUEI4ES,!$WED#<\F<!%'5C["K6H7]S+$EMIQ,=M%T7&&D]
M7;W/Z5?+8SA551\NQI^+]5F<1O8S*D-JP 0<<]C_ /6K TR^N(I9)UGV@AI9
MNV*I1V\MXWED-+(Y+;MQ(4>O%6X[<PZ<L:$,;ARK''.U>?U.*)I.W*4DXIM[
M(ZU=?CAMK<32I$S@.3CM4=WXB,T,@0$H!D,AR,=\UC6]K)%(KB),CG#+D5(;
M2.&57C'+?>4=.:TG&44E(Y4DI.7<F\Z;4 OF3!(P1MBQ]X>N:TY%2) ,@8'K
M5=H38QJ GF1+\P*]1GUJE///>R$1Q,4';%9J/,[!S6)C<1%\KU[D4]H&:)I;
M1@<_?CZ ^_M4!TN1_P!ZQ";1]VEE LX24W^9(-H&>U.24963"SEH0IIUQ<3?
MO&:-3U'?%:$5C;VDK*F=H7<23S5./4&MQBXM&^JN<U6GNI)E0P,/)=]K<8*G
MMGVI-M@HV>IHVFGP20M+*KEW8DG<:J36R)(0K;XNC(_/'M4S7PAMPC/M ZD5
M5\QI9D6/YU;J134)6Y@;ZC3,^F'[(0Q4<Q2#K_\ KI]O;7U^6C<A5/.YAS5?
M46EM]1&/,((4[1_C6I)J$EK;C[1;3Q,1P^=P%4I-*R8G%D#0BW@EC+,'.%7;
MUS6W':36,$8W1SEU#9/&*Y:\O&DN%:+_ %)&/I6_!=L+9 \JC"C!/.:E*3=D
M4TK6*^H7LZR!9;4;>S!\C/N*Y^62[AU/S-0*XDY5@>*U;S4B1ND"D@X!0U6O
M"ESIK&5?W>01S@J3W%%G%VD3OHAK3XY6;!'8T^&_9\AA[YK/M-,D<;7EX[';
M6DUF89(UCC(5N&)[>]5-IK82;N5WT^9[DM:2*L;\E6.,5O\ A?2%@UB"2::(
MR MA58<?*:FT5;2;S7D6-BI"(",X K7M8[<ZO;$!<Y;!V?[)[U$6V[)%3@K,
MSK6V+D%N2ISN/:I8M,V:D]W#>2IN;.P'"D>]5]1UFRMK5(;)UDP?G<=S6;_:
M<C*OSG:WH:4%*]D.5FCH[RU:]UAKJ6=H;=K00F2&0!B<\C'H139M.TLB%X9Y
M[=500;D8<KV!R/UK&2YD#+&A+$^]:;VB_8Y(KAB/-7! [5TRQ$XOEOL<:P5*
M[NMRW-I=E>3SL9;E//B$4BHW# =#]>*F/AO3TM+@S7-P$G5!(-RC)4Y!Z<5S
MY:XTY (GEG51P6E.ZLZ6]6\N%+I*LH/!,I./P-)8B=M)">"IMZH['4FTS4[B
M.<SS0S1(8Q)$1DKZ'(-17=EIUTRE9[F)C"(',<@_>H.S?XUS$%M/&C-'(78]
M5/'%7+2RNG4ORH[ GFBG7:W9;PM)MW6YTEG#I]K?-/"6RT*P>7GY0J]*ABTF
MTLGE2WFGQY;B*)W 12P/MD_C5<V\=A;J\S%I'(5>P'N:?]K0HYWAEQR6[U'U
MF:8_J=*2V&Z?8QZ/965S/(\]Y;1%4A,P,<;'J155]5:ZFEEN.';'RCL,=*SK
MRWDN S6K-L'4$_RJ:RM!*@#Y+@8^6E7E.;O,UP]"-&-HDEQ/YJ (0LG=33[9
ML9*QE9.Y]:=:Z,LUP'FE4Q#I@<UNNEA90B0=NHSUJ)N+2LM37F5S&NQ$\\<%
MSM$VP,.."#_6M2TDM[",']V#C^\ :Y>]M!J4K7<ERR3.=PP> .PJ@ME<-U&X
M9X.>M*,7+X43)'4:EJ"7;0Q1A2@DWRE3D''05$;B1@ K8YY]<5B644MM<"0<
M'H16Y<0^9$LD2D9_N]14K1W8[Z:%:>2.4E?,+$=0>]2Z7 (;I6C0+N/('>KN
MF6,,9WRC?)_M=!4VJWR6EMF!$$AZ$#O53?,]%8+F3!<$7$L)D\LI,Q".>2,\
M$>U3W+3R@>6\1P?O9[5BK:O*AD)+2L=Q;N32))<(=O!(_O"KBVGS(DZ.QLE_
MUEQ)N<^G047B$/&(!D+U/<UE:?:SZG*T+WS6S*I9=B9+X!./3M6;97UQ)=P1
M"1@)9%C+$Y(R<9_6AWEJQ*7=FW<7<13R+EU\M^C$<PM_\2>]<[-HDANW5HV+
M \XY'M6Z;6&ZO2D4LEP(+T6<ZR($;)S@J>F..]6('O6@MDA$3><2MNGF#=M!
M()QZ#')JGS<O*9\]SD]3T6[@MEAMUD3S7#; V-QP:SOLME"L<4\?DSQC:^3G
M<:ZK4=-U2ZN2)FMXXHT67SY)<1$,<#GU)&,52NM*GM]'&I>?8!GF>-H8PIZ<
M<'G)]AVYJ8<T7L;^T@TDWL4])CN!IKF ,K&\CV;>,_*]:FJ6T-SKES(#E6V@
MY_O;1G]:CM;2_M]-CN3<($DQ)'"TH5W .W*K]3CBM5="NC>HMYB..19,F)\E
M75"V#4J$N;F)G5BU8H16D#G;!%]W@MBK-_;*E@D*_-)/(JHHZDU8@DAL(+"/
M<?\ 2H(Y7W>K'M4=]87LFK'[!*/+@FDM02V"IVY)/H-O>KE>3NR(U%N4+I4M
M+8V4+*3G,\B_QL/X1_LC]35 6V\;AD$?W3S6I%I,ZSV N%C,=VRA524;R"#@
MC(QVJ+^SKN&U6_;RD@<G8A?YR,XSCI3E#2Z",TFFC/\ -^PN63!1_P""%-K.
M1_>8]O85=TF.VNP&E5(W5=JHHX'.:O7T8ETJVD(&X,PK%D@,9W*2&]JRMU.B
M59M6Z&\--0S9:8<]EQ1=_8K8?NP %'/.<FL*VU*Z28(S;X^ASUJ[+8-+Y4CR
M[HY,\CM_D4V9KE6I4%[>"Y>2")3&QR2YQ^5!UXPN?-MY 1WB<'^E3W=OY:8C
M_> =#5,".%3(Y ./N>M7RQ4;W!RN2/?374$EQ;S-M0C<KCY@*LV062XW2@[A
MC!:J6E8F=U^ZDGR\U=GEGAV1-"PV#&<5FP<M"Q>S0./N$+_?JC; >7<A$4JR
M9P>AQ4L5G--%F5\1CKZFJUY-Y,#P1\,PY8=5'^-:3C!6Y02NR.W2"YCW,)![
M$\5H>;:PP;8\8CY('<USPCFB56B:5#]>M6(;BZ1A]HB#QOUR,9I-6W!**9M6
MC^??^?<(/E7*CMD5:OI\ J0&S_$!5.[G>R>(1_- Z;HSC]*KM!?WH 4"-",9
M/7%$5'7F%S]R"(0_:"8<;6ZC'&:KQK-(66WD_<$_=(/R^U7&@CTN!RIWR8VH
M?5JHZ9ILLC ^=(@!Y*MS4H>Z29I6.FV:9-Q^\D[*3C%4M7A:>W2T0@9DY(]!
M_P#7JW=+?Q+NANGD4?PN<U3C#WS&XV_OH1EU7^(>P]:8K)#O[)N+*,&&1P .
MHJ-=0O60Q7!$D1X+ 8(J>^N/M.QDE9D*CA3TJ"U!*,J*W#<9%.WNWN)/L%C=
M-ID\EO,W#?-&V>HK?\/ZP]SKEK#AF7YA^2&L;45ACCMTND!7D9(R5-;/AA;2
M/5K4VTREVW90\'&T^M5";CMU'.]G89JUA T,<Y7&9 &"\;LU%;Z7&7!#';G[
MI[445E%Z#GNC>L[6*T@>=QN(!P/2J*7[SS;F[\T45+&MALK_ &J5D'R8./K3
M4T](IPV Q/=NM%%=%2*C2BT-$?B%1:I92([QS!BVY.Z^E2KKV+<#8Q8#KFBB
ML$W8M13W*EY-<3VR7#3.W[P#:QX'TIGGO$H4G/\ $#1133UN1/1Z&OI-M+J:
ME"ZI&.3@<FK^HVO]B:;)=(VYE^Z,=^QHHIN3GK(+LY6._O+%B#,=TGS$J?6C
M^T+F[=4:5B,_Q&BBBVA*;N;D>G*UOYD389.S=*I0AI[U8X\(.G6BBI3:V"_O
M,Z2VT../<TK[\#) %9GB.1X)H((&,9"[MR\=:**41-F8)+C:"UQ(2?>M2QT\
M7=EN=R7&<9HHI@VQ1%&JD;<,IZCI5FVL/MBDXC '7UHHJHR:32)0DL/]G1F:
MWVB0!ADC(Y&#_.L-D;=;2J(D>W"A-J8!VG()]3111?032N-N-3O7NHI$^S1;
M)_M!6.+:'D_O-ZU+:-=?;;*5945[7<L9"]F))!]>IHHJVV2HHMSM/!>2EA;O
M%( CP-%F,A3D<'N#WJI-(TD$E@R0^4TID4B, HQZ[<=***N#=V"2N7!8SKIJ
M02- RQ+MCD,0,B+G.%8].:JZIJ]];WMK*I@,Z@NS&/A]PP<CZ?2BBLXMARHQ
MKZYN+P6@F,>ZU4+$R)@X!R ?7':MBWUMI(K\-D7M\-KE%"QKQC<!UW$$C\:*
M*:;!)$5KKUU;^59JD"?9G5E*1\$C@$__ %JTK*:5[%K/$(@?[X5,%N<_SHHH
M;8^5#;U8X8$MT!(WDY/TJJ]I$$!<9+#-%%7A_B-.IGW-HL&&CZ,>AJYICEXY
M86P05+#/8BBBE724]!):D2)!=H'421D]@W%"Z)!+*1(6;'J>M%%9$L;=-!IG
M[R*+ 4?='0UD#6I59A+EP3R,T44D;1^$=/K?F1*L?F(IZCBEB02B(MG:_P W
M7)QFBBJ6PY)(LX2 L?F8+R 15.:\:6X5!PK=0?6BBCGE)69C<N:Q-)96=FRN
M=I+#:/SJHVMSA $].<T44EL;J*:N7TL1>V@N!(PW)O"D=.QJ2T410;%[GK11
M505YI&?VBOJ3;;;>N05JAHL[1W F7J#D^]%%:XC1HF7Q$\\MH=7F$4#*=QX)
MXS5S/F($VJHZ_*:**QD5&*,RYE^U31J0=HX&:U_#MU(->M(&6-D!;;D9(^1N
)]%%$5J*IU/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" %9 @$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/..6.!0 ME>-:2R,@^=E !]/F!Y]N,?C5UM54-*L<&(92H9"<_($VE0>WK^
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MV!BBI-GM10,KW')!J6-1Y0-$J!E&.:55/EXI@+MXIFPEL4\*0,9IT<9+9S2
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MP27.<US+FOH=UD._LB;_ )Z1_G13OM<?_/;_ ,?'^%%+GD5RH>L"SW B\]B
M23G&TTDUK&LH5[QW8G.$  ^E+#ISPV+M:R&61C]Z0X %,L[%X!O>9)9E!**H
MX_,]Z:=MGZ")9M.N3N$5PD<( P"I)]\TBH+&$3@B>8-M 4<Y]A6=/J%S,)%@
M#,P/W!DFB W,-IF5-LC#DGGY<XX_' /X>M3)M1W!:LN*;Z?+S2Q1ANBXW$?C
MT[^]5X],>[DN#YP\](LHK<#@\\?2E\P3.(7<8*Y##H!_2I+&=;34HS,^X$[<
ML>JGH:F<)*-WOY!&HG9K;S,]=/ABVO(7GDQ@%SP/;%7XVVPE&6#' *XZ\]*=
MJ<#M=S1Q1R.5; P.,=JJ:?$S1M$T8:1G.">WX4[*HF_UN1"3A:+?X6\S1M;!
M1=ADE$:,"Y*GD>N./>J-QKZ^0;:US+>PW31@R'Y-JG@D=]W(Z\5>U:PGTW0W
MOHA<&Y0D!(QD'/&YAU 7&<COBN#MA%Y2R;Y"ZN-JKTQW)JHMI\K>AK&"E%S2
MU_5]S9U'7-4EO)XX]T(N,1R6]J=HX&.2>>@]:L:3X@MQ&FDZO(8DCR([@@Y!
M)SB3L1_M?_KK*N;>*:-+F.7$V2=X/!JI>0S6\R&X7YG <%@"3_0_2KG'V:YD
MQQC&?NM67XW7Z'71:==:K.&@DW6\;E5D< (?=<$[A[^U&JV%A8HMM'YC,=S-
M.S;<'V%6]$O]2U/08SM@M%PT>1\K-C@,H&%5<YX&?UK,U:>Y@1H;RSW(#@2!
M\Y]\5*7/\3_KN8R]V7;^MC*M=.N8+Q/)N4DC;H9#@@?AUKJX+>*UTB5[RYMG
M9R!&%&[:>I]L]/I7,()65#$,*1\H/&?IZ]!4NJV6I17T4,4,TT=K&-[# C21
MN2OID< TI?$ENEW,U:S:^+R+E\U^6,\,B7,8^]L/S#ZCO^%-TB^^VW:VT38?
M^+((V^N:HQWTJS&-[8V\S94JR_*WXU.)I+H$POY5RIPQ_P!D?WCZ5;BXQM>Z
M+Y^9ZZ?U^!KFPMXU8-<S ]=HQA?;WJ'R+41ALB;8226[#Z=Z+>POFC1II(D+
M#."2>/RJ>+33!-YLDBO& 20O>IZ;@WY#XIH2"5ACW$;=RX! JTM[';)D*$5$
M9Q@<<#/]*J6]E9QCY=Y/KYE2:G+&N@W4:#9N01[AU^9A_P#7JM"6VV<S86PD
MB\QIRNXY)(RQK:L+-9$<PS,S@<,_0&L9+&=ID >..->F>2?PK8=SI]J@C),9
M_CZ?-[TFWW-2Y#IIMGD::0.TH *J, $<<>O%:FE61AV.OFO(O(#J2*Y5KB[N
M+N,8+H3U!Z_2FBXG-XV9_*4+\HWD97J,?4&FJKB^5:W%[&\6V[)?UH=K=:O9
MZ7YDCJ[R*P>1(@>-W&2>G;I7':W9W.J:BM^)EBCNE+9C/X;<_A4) >/=;2LJ
MN,&,<9'?_P#75V*Y4Z1/" TGE$$ <G![C'M_*LZDG%IVNO+_ #-J=)<K2W:Z
MZZ>GJ96GQB"/S(X8RJ''S#)_.KT:0WLVR18@YZ.#@J>P^E9\MI<Q3Q81A"S
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MUPXD&"6[Y'7.:<4G+4%\%^WD/DM6C6:2Y+R2@_*P;<&]S7=>&M8BU:VCTG5
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MA2#_ "J]:QBYVB([$');O3TC:PG=DCQFWM)KJ23+QQ,P ^G'ZURUA;N;?<&
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M#[OM#Y_W15HZ#&8T42D%.C;>:3IL/:Q1Y^VGR-,6EVJ'.240#-:BPJT&[HZ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!C_VU*'<>0K ,1PQ]?I4BZV#C
M= PS_M#^M9;#ESO ^=N-WN?:DQS@E#VRV34W9V>R@^ALC68.\<WU"Y'Z4]=7
MM&Q\[#/JA_PK#P.I5L=^!2D$'Y@5'H.!^M%V3[&)OKJ%JW_+=!]>*D6XA;[L
ML9^C"N;^;IN.#U!S2&-<?,F?^ C_  HN+V"[G4@@]#FEKE@JJ.%(&>"H'7W-
M/$DJ_=FD7V#FG<7L/,Z:BN<%U=+C%Q*/8G_$5(-1O%R3-E1_>4 T7)]A(WZ*
MQ%U:YS@B$_4$4]-9FR T"?4.<?RHN+V,C8HK,&LCC= 1]&%/&L0?Q)*O_ :+
MD^SEV-"BJ2ZK:M_&P^J'_"I%U"U?I.GXG%.XN678LT5&MQ"WW98S]&%/!!Z'
M-!(M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 445%)<P0_ZV:-/]Y@* ):*SIO$.D6_^MU.S7V,R_XU
M1E\<^'8L[M5A;']P,W\A4N274TC1J2VB_N-^BN2F^)?A^+[LUQ)_N0-_7%4I
MOBQI2Y\FRO9/J%7^M2ZL%U-HX+$2V@SNJ*\WF^+R8/D:0Y]WG _D*H2_%S4C
MGR=-M$_WG9O\*3KP[FJRW$O[/XH]7HKQF;XI>(9/]6;.+_=A)_F:HS?$+Q+-
MUU(H/^F<2+_2I^L0-5E-=[V/=**^>YO%>O3Y\S6+[!["4K_+%4)M0O;@_OKV
MYD_WYF/]:7UA=BUE$^LD?1LMW;P?ZZ>*/_><"J,_B;1;;_7:M8K[>>O^-?.S
M ,?F^;W/-)M4= /RI?6'V+_LI+>7X'O<OQ!\,Q9SJ\+$=D#-_(50F^*OAN(D
M+-<RX_N0-_7%>)D9I,"CVT@_LZDNK/7IOC'I"_ZBQOI?J%7^M4)OC.N#Y&BO
M]9+@#^0KR_KD4A&.]+VL@^I4ET/H[^U6_P">0_.BJ%%;W9YO)$:4W%N !N;D
M#W-+L.<[1^"\?K4RID'Y5 W'DCW-+Y?LO':F:<Q7*$C 11[XY-'EXX^7CN,5
M8\K#9X)/;K0(^. ,>I[?X4!S%<(>F"/PQ_2CRSURI]C_ (59\O\ V1]0.:01
MX.0 ?KS0',5]F3^O _\ K4OEYYVGZ8J?9QT ]_Z4>7P.GX'^E <Q6"9/3'N3
M2^7[ _3_ /55CROQ/US2M'GL ?9>* YBL8_7./0C&?PQ2>4,=1SV'^&*L^6>
M#M!]N:/+/^S_ (T!S%?R\#C:1UZ9_.CR^"-H/K@9 JQY?(X7ZXH$9[#'^[0'
M,5Q'CMV[KQ^%+Y>1C ^G?^56/+)'4@8[G_ZU(4R#W([D9_I0',5_)S_#GU^7
MC^5'E = J@>V#_*K!C_"E\L _-DCU7DT!S$"M(,;9G4>SG-2+/<K_P MYO;O
M_,4[RP?[V.V[I0(_\^O^- M!1?78(VR%O]Y!_3%2+J5T.HA./4$5'Y?3&1[D
M8H\OMG]>*8K1[$RZK-G#0(3_ ++G_"I!JW3=;MS_ '6!Q57R^/ND =P*#%_L
MG/<$ 4$\D>Q=&JP]XY1[[<C^=/&J6W=V7ZH?\*S_ "2>J?@%X_&F,8X^9&50
M/4@4"]G%FLM_:MTG3\3BI%GB;[LJ'Z,*YYK^QCR&O8% '_/457DU?25X-S"W
MT4M_2DYI;LI8>4MD_N.L!STI:XU]=TU%W*)FQ_<B(_PJL?%T"'$45\?JX7^M
M2ZL%U+6!K/:+^X[NBN ;QM,H8Q03\=-\R\_^.FF-XVU8(&2.V _VP3_+%2\1
M3[FBRS$OH>A45YP_C?6'7(DM4SW6(G^9JK)XIUUS\VH84_W(T']*AXJ!I'*,
M0][+YGJ-%>/S>(-5D.UM2N_<^81_*J<EY=3MNDNIY!Z-(Q_K2>*71&L<FJ=9
M(]HDN(8O]9*B?[S 54EUW2X?]9J-HOL9E_QKQN6)6^8*3GKD9-1B-1_=7TQ4
M_6NR-EDJZS_#_@GKK^,-#CSG48FQ_<#-_(53E^(&AQ?=EGD_W83_ %Q7F/[Q
M4.!U_.HB-V0-Q/<&I^M2[&RR:BMV_P"OD>CR_$O35.([2[<^X51_.JLOQ-0?
MZO33[%YP/Y UP  ;)8<#K31M5^<X%2\1/N:QRK#+=7^9VLOQ,OL9BLK90>F6
M9O\ "J4OQ#UQS\K6D0/]V(G^9KF4_P!I<8'!IOR$$X!(["I]M-]3:.7X9;01
MN2^,_$4N?^)CL'^Q$@_I5&;Q)K$P.[5;S\)2H_2L\,C _>&>U1  D@DCTJ>>
M3W9JL-1C\,%]R)9KZ[E_UUW<2'T:5C_6H71  6Y)]>:4@G &<"F<Y.!TI7;-
M%%1V0T+QG:*8W!J1G;H:CR.] QA--/Y4XBFD>] #3333C333$--)2FD- A*2
M@FDIDM">M(>:<::33(:$HZ4=Z2G<RE$0_C0:6FM57,W$^@****ZSP"W$F8\X
M[GW[FG^6#U!_ 4Z$?NA]3T^IIX7VJS.Y$(\?P@GZ4FSMU_E4^P\_+^8IK,B<
MLP3W) H"Y%LZ< FEV9Z#]*8]_91_?N[<?]M%S4+:UIR]+M"?]D$_R%*Z*49/
M9%CRP.WX4>7@] /]ZJ3:_8K]WSG_ -V(_P!:C;Q%"/N6L[?7:/ZTN>/<M4*K
M^RS2V$=O\11Y?KS]#60WB)C]VR_%Y?\  5#)X@O,9CMK<>V6/^%)U(HM86L^
MAN>7U(QGT% 0XZ ^Q%<XVOW[L%5X$/?$.?YFH)M9U N0+M@!_=11_2LWB((U
MC@*S['5>7D=Z41''W<CZ5QC7U[)G=>W)]@Y'\JA+M(N))96.>K.Q_K4?6H]C
M59;/K)';-M3[[HO?YB!4+WUE&3OO+8>QD%<@D,;2@@(<>JTDI.<% !VP*'B=
M+V+66ZV<OP.I;6M,7@7<;'_8!/\ (5&VNV0/R^>Y]/+/]<5S2;0A9CSVI(P7
MD#,?UJ/K,NQHLNIK=LZ"3Q';1_\ +K.3_P !']:@;Q.,'99X]GE_P%9%UC<O
M6JY SSVJ98B:=C6& HVU1KOXINCQ';6Z?0L?\*C;7M4?&WR%!_NQ?XFJ&P-'
MOY4#M2-(#!M5B"*CVU3JS582BMHEE]6U23(^ULI_V45?Z56DU&]SB2\N2?:0
MC^50'<<8;.*?&RY_> D>M3[23ZFJH4X[17W#6=Y#AY)&8]2TA/\ 6DCCA8E9
M$!/J13V4.Q(&U?[U(YB"@9RWK4W9JDELALMNL.-N<'L*KY_O#:!W-3HSJP#/
MU[4XVPWY=@1VHM?8J]MR#S1$IVDL#UIJ!78[VR*=(4CDP#P:8$7S"0WS=ZDI
M$3 &0A6(I&WA\!AMQWJ3*.3N.0.X%0D;]VQ1CL:8Q&?9C@;3_=I_E1^6&8GC
MM3$4J&/'T)J-<M(!D\>E QC,"_R)D#K[TY"4<D(3GL:>?ESMYQUP*@8%2-V[
M:?3K0,'="Y)#!O:F ^7AL<-Z]JE>)1'NR<GL33'5O) *@"@!DC,<;E!/J*8K
M)C^('^]4@3 !R5'<'O2^5AMJDX/J.*>@#%D51\WS _G4;[=Q;)^E3L(L;%ZU
M"(^< KCW% QCDG^+&>@IH5E!8\8[FG %GX(8#VI)&+$[N@Z"F(C( ((8\T!L
M9&1]:4+\@SGK2G8K8/3VH C*XY!Z4ASCY<\U)*0>%(^E1G<1@4 1/UY/--XQ
M[U(>,Y'Z5&>3TIB&M3#Q4K*, YJ/'6@!AIIIY'O3#3$--)2FD- AM)3J:: $
MQ2-2_P J0FF*PA..:3(I3Q2=/<T$M!SZ4G;F@&D/Z4[D.)] 4445W'S!H/I<
MS9":C<QJ22 BIQ^:U7;0)7^]J^HGZ.H_D*V:Q]2\2VNDZH+2\!CB%G)>/.>5
M1$95.0.?XZNR.=5)+8A;PI$_W[^];_><'^E,_P"$.M/^>\Q^JI_A4EOXTT.Y
MNX[6.\/G22B$*\,BX<C*@DJ -PY&>O;-0+\0?#;)O&H_)L$F[R),;"<;\[?N
M@\$] >M+DCV-%B:JVD2CPE;K]VYG'T"?X4O_  BL/_/W<?\ CO\ A5L^(]+$
MA0W0W"Y:T(VM_K53>5Z?W><]*J0^-=!N+:6>.^S'$B2$F)P65SA"H(RV3P,9
MYXI<D>P_K5;^9A_PBL/_ #]W'Y+_ (4O_"*P_P#/W<?DO^%78==TZXTB34TN
ME%G$',DC@KY>W.X,#R",'((S6-:^/=.GO-064O';6[PQPOY4GF3-(A;:(]N[
M( /;IS1R1[!]:K?S,N?\(K#_ ,_=Q^2_X4A\*0$8^UW'X;?\*EB\6Z-/<VT$
M%YYKW*))'Y<;L-K$A2Q PN2".<=*B'C?0#!/-_:*"* *SN8W *EM@9>/F7=Q
MD9%'LX]@^M5OYF,7PA;I]V[N?_'?\*!X.M@<_:KC\=O^%2:9XNL-6UNXTRVC
MNA+#%'+ODMW16# GN..G?&>V<&MVE[*'8/K=?^9F /"=N.EU./P7_"FMX/MF
M.3=W/_CO^%=#13=*#Z!];K+[3.>3P?;(<K=W&?\ @/\ A3G\)6[C#7=QCZ+_
M (5OT4>RA:U@^MUOYF<Y_P (9:_\_=S_ .._X4?\(9:YS]KN?_'?\*Z.BE[&
MGV']<K_SLY]_"%NXP;NYQ_P'_"F#P7:9S]JN?_'?\*Z.BATH/H"Q==?:9SO_
M  AMMT^UW6/3Y?\ "D_X0NTSG[5<_P#CO^%='11[*'8/KE?^=G.-X*LV&#<W
M'_CO^%-_X0>S_P"?JZ^F5_PKI:*/8P[!]<K_ ,[.<_X0NTV;/M5SC_@/^%1_
M\(+9?\_5U],K_A73T4>RAV#ZY7_G9S'_  @MEG/VN[_-?\*<_@BSD W7=UQZ
M%?\ "NEHH]E#L/Z[B/YV<R? MD?^7JZ_\=_PIH\!V(&!=W?YK_A7444>QI]@
M^NXC^=G+CP%8#.+FZY]U_P *#X"L#C_2KH8]"O\ A7444>QI]@^O8C^=G*GX
M?Z>01]INAGT*_P"%-'P]TX+C[5>8_P!Y?\*ZRBCV,.P?7L1_.SE!\/M/4Y%U
M=Y]<K_A2O\/[!^MW=_@5_P#B:ZJBCV,.P?7L1_.SDA\.M-!!^U7G'^TO^%*?
MA[IYQ_I5YQ_M+_\ $UUE%'L8=A_7L1_.SD7^'.FN?FNKSZ;E_P#B:4?#K3A_
MR]WO_?2__$UUM%'L8=@^O8G^=G(GX<:8>?M%WGUW+_\ $T@^&VE@Y^TWA/NR
M_P"%=?11[&'8/KV)_G9R(^'&F#I<W8^C+_\ $TW_ (5KI6<_:;S_ +Z7_"NP
MHH]C#L'U[$_SLX\_#32F.3<7G_?2_P#Q-,/PPTENMS>_]]K_ /$UV=%'LH=A
M?7L1_.SC1\,M)7_EXO/^^E_^)I/^%8:3G/VF]!_WU_\ B:[.BCV4.P_KV(_G
M9Q;?"_2&ZW-[_P!]K_\ $T?\*MT<#_CXO?\ OM?_ (FNTHH]E#L+Z]B/YV<3
M_P *KT;_ )^;[_OM?_B:/^%5Z-_S\WW_ 'VO_P 372Z]JZ:#H5YJ<D32I;1F
M0HIP6JI<>,M$M;M[6:[83QR&)D6"1OWF-VP$+@M@Y ')H]E#L'U[$?SLP_\
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M5DU@:A$PD9#-'\W[ML+\NW=QU'TH Z.#PKI\7AB?0W+/;7"NLK *C,7ZD;0
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H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
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M.<9!^AZ53\0?$#1?#E^+"Y>XN+W;N-O:Q&1U'J>PJ?PWXUTGQ5)/%ISS+<0
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;444444444444444444444444444444445__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
